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1. Summary 
 Teneurins are large transmembrane glycoproteins that are well-conserved across phyla 
and show their strongest expression in the developing central nervous system (CNS). The large 
extracellular domain (ECD) includes several structural features like an NHL repeat domain, a 
predicted beta-propeller, which is responsible for homophilic rather than heterophilic 
interactions. It has been shown that the homophilic interaction of the ECD leads to its release, 
and the subsequent regulated intramembrane proteolysis (RIP) of the intracellular domain (ICD). 
RIP cleaves the ICD at the membrane, after which it translocates to the nucleus, where it is 
known to affect transcriptional regulation. 
The first part of my thesis discusses the evolution of teneurins. Teneurins are ancient 
proteins that are well-conserved across phyla from unicellular eukaryotic organisms like the 
choanoflagellate Monosiga brevicollis to higher multicellular organisms like vertebrates. The 
study suggests that teneurins may have evolved from a choanoflagellate via horizontal gene 
transfer from a prokaryote. It also describes the structural features of teneurins in detail, and 
identifies splice variants of chicken and human teneurin ICDs. 
 The second part of my thesis describes a novel molecular mechanism in transcriptional 
regulation for the intracellular domain of human teneurin-1 (TEN1-ICD). We identified several 
new interaction partners of the TEN1-ICD in a yeast-2 hybrid screen. Concurrently, we 
performed a whole transcriptome analysis of a glioblastoma cell line engineered for inducible 
overexpressing of the TEN1-ICD comparing induced to non-induced cells, to determine potential 
target genes. Results included several microphthalmia-associated transcription factor (MITF) 
target genes. Interestingly, MITF is directly inhibited at the promoter by transcriptional repressor 
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histidine-triad nucleotide binding protein 1 (HINT1), one of the novel TEN1-ICD interaction 
partners. Further experiments show that the TEN1-ICD competes for HINT1 binding to 
positively regulate MITF-dependent transcription of target gene GPNMB. 
 The third part of my thesis discusses the NHL repeat domain, located in the ECD of 
teneurins. Since this predicted beta-propeller is responsible for homophilic, but not heterophilic 
interactions in chicken teneurins-1 and -2, we were interested to learn more about the structure of 
the domain. For this, we started by purifying the NHL repeat domain of chicken teneurin-2 and 
set up drops for crystallization studies, to resolve the structure by X-ray crystallography. We 
have set up the purification protocol, but have not yet determined the ‘right’ conditions for 
crystallization of the protein. 
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2. Introduction 
 The interactions of cells with either, other cells or the extracellular matrix (ECM), are 
fundamentally important processes as they determine the structure of all multicellular organisms. 
In addition, the interactions are involved in crucial biological processes such as cell-cell 
communication, immune response, and embryonic development. Examples range from epithelial 
cells lining the gut to axonal pathfinding and synaptogenesis. All of these processes have one 
thing in common: they require transmembrane proteins. These proteins connect the cytoskeleton, 
usually through linker proteins, to other cells or the ECM (Fig. 2.1). This link is needed as the 
plasma membrane of cells is too weak to withstand strong forces.1 One example of such 
transmembrane proteins is the teneurin family. Indeed, teneurins can connect the cytoskeleton of 
cells to other neighboring cells, while at the same time having signaling capabilities.2 
 The introduction will start with the ECM, its significance, and how cells can interact with 
it, followed by an overview of cell-cell adhesion. Next, I will continue with early neural 
development and brain patterning, and get more into detail with axonal guidance and 
synaptogenesis, both of which are developmental processes that teneurins have been implicated 
in. I will conclude the introduction by giving an overview of the teneurin family, and what is 
known about it thus far. 
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 Figure 2.1 Cell-cell and cell-ECM adhesion molecules and junctions (adapted from 1) 
Overview of the different types of cell adhesion molecules (CAMs) and their involvement in 
cell-cell and cell-ECM junctions.  
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2.1 ECM and Cell-ECM adhesions 
 The ECM is a crucial feature of multicellular organisms. For one, it gives organisms their 
structure and acts as a scaffold. Depending on the tissue, the quantity and the composition of 
ECM can vary significantly.1 For example, in bone, ECM makes up more than 90% of the 
composition, and has a very high tensile strength, due to calcified collagen I.3 Conversely, in the 
gut epithelium, ECM proteins are much less abundant, but no less important.1 The basement 
membrane is a specific type of ECM (Figure 2.2) that acts as a barrier to other tissues and can 
help to selectively filter nutrients of certain sizes.4 Thus, ECM does not only have a structural 
role but is also involved in a variety of cellular processes like cell proliferation, migration, and 
differentiation.1 
 
Figure 2.2 Schematic drawing of the basement membrane4 
The basement membrane consists of several ECM proteins and is anchored to the receptors of 
neighboring cells. Laminin and Collagin IV form independent networks that interact with each 
other and the other ECM components. 
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 The most abundant, and probably the best studied ECM proteins is the collagen family 
(reviewed in 5). Collagens make up around one third of the total protein mass of most animals 
and mostly acts as a scaffold protein. Collagens are defined by the presence of one or several 
triple helices called collagenous domains. These domains are composed of three polypeptide α-
chains coiling around each other to form a triple-stranded helix (Figure 2.3). Even though there 
are at least 46 different α-chains found in vertebrates, potentially leading to a large number of 
different combinations, only 28 collagen molecules have thus far been identified.6 Collagen I, for 
example, which constitutes about 90% of the collagen of multicellular organisms, is made up of 
two α1[I] chains and one α2[I] chain, which is typically written as α1[I]2α2[I]. Other forms of 
collagens also exist: network collagens, anchoring fibrils, fibril-associated collagens with 
interrupted triple helices, membrane-associated collagens with interrupted triple helices, and 
collagens with multiple triple helix domains and interruptions.7 Since collagens are such 
important and abundant proteins, they are also involved in numerous diseases. Mutations in 
collagen genes can lead to chondrodysplasias, osteogenesis imperfecta, Alport syndrome, Ehler’s 
Danlos Syndrome, and epidermolysis bullosa.7 
 
Figure 2.3 Collagen type I structure (adapted from 8) 
Example of a collagen triple helix. Pro-collagen forms in the cell into a triple helix, is secreted 
into the extracellular milieu, and is processed into mature collagen by collagen peptidases. 
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Another important family of ECM proteins are the proteoglycans (PGs) (reviewed in 9). 
They consist of a core protein that is covalently bound to glycosaminoglycans (GAGs). The only 
exception is hyaluronan (HA), which is part of this family, but is made up only of GAGs and 
lacks the core protein. GAGs are long unbranched polysaccharides with a highly negative 
charge. There are two types of GAGs: sulfated GAGs like heparin, and unsulfated GAGs like 
HA. All GAGs consist of repeating subunits. For example, HA has a repeating glucuronic acid 
and N-acetylglucosamine disaccharide subunit, which can extend up to 25,000 sugars. The class 
of sulfated GAGs are generally bound to their core proteins via serine residues. One exception is 
keratin sulfate, which can be linked via N- and O-linked oligosaccharides. It is also interesting to 
note that the same core protein can differ in the number and types of sugars attached to it, while 
even the GAGs themselves can also be modified.1,9 
The core proteins of PGs are a very diverse family of proteins, which can be divided into 
several subgroups depending on their location and binding: small leucine-rich PGs (SLRP), 
modular PGs (hyalectins and non-HA binding PGs), and cell-surface PGs (Figure 2.4)9. The 
heterogeneity of PGs also leads to a great variety of functions. Originally, like most other ECM 
proteins, PGs were thought to be mostly of structural importance. The GAG chains tend to be 
very hydrophilic and stiff, which can be helpful in forming hydrogels that can withstand very 
high compressive forces.1 These properties are very important in the knee joint, where they act as 
natural lubricant.10 However, PGs also contribute to other processes like cell adhesion, 
migration, and proliferation. One of the hyalectins, neurocan, is even involved in inhibiting 
neuronal attachment and neurite outgrowth. Another example is the SLRP decorin, which 
functions in signaling, as it can bind to multiple receptors. Decorin has been shown to inhibit 
transforming growth factor-β receptor signaling or regulates fibrillin-1 synthesis. Thus, PGs not 
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only serve a variety of functions, but are also distributed in many different types of tissues, 
ranging from cartilage to the CNS. Mutations in PGs also cause several disease like Knobloch 
syndrome, intervertebral disc degeneration, and Schwartz-Jampel syndrome.1,9 
 
Figure 2.4 Overview of the proteoglycan family9 
Classification of the heterogeneous PG family, based on their location and binding. (1) ECM 
PGs like SLRP, (2) Modular PGs that are divided into hyalectins and non-hyaluronan-binding 
PGs, and (3) cell-surface PGs like Syndecan. 
 
Another family of ECM proteins with a very unique structure are the laminins (LMs) 
(reviewed in 11). The LM structure is rather unique since the chains form a characteristic cross-
like structure. Many Christians have thus dubbed it the ‘God protein’, as they believe that it 
proves the existence of god; a theory made popular by the American preacher Louie Giglio. LMs 
consist of an α, β, and γ chain, making them heterotrimeric and quite diverse (Figure 2.5). At 
least sixteen isoforms have been described thus far, which are named with a very simple 
nomenclature. For example, LM-521 consists of α-chain 5, β-chain 2, and γ-chain 1. There are 5 
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genes encoding for α-chains, 4 genes for β-chains, and 3 genes for γ-chains. LMs are vital in 
many tissues and processes. They are one of the major components of the basal lamina12 and are 
involved in cell-specific processes like differentiation and adhesion11. For example, laminins are 
part of the basement membrane of the blood brain barrier.13 When binding to certain integrins, 
they can also induce signaling pathways, like LM-521 binding to α6β1-integrin (for integrin 
nomenclature, see below) activating the PI3K/Akt pathway, thus keeping hESCs pluripotent.14 
As one would expect, some laminins are also associated with diseases, like mutations in LAMB2 
causing Pierson’s syndrome15, and mutations in LAMA2 causing muscular dystrophy16,17. 
 
Figure 2.5 Structure of laminins11 
Overview of the structures of the laminin family of proteins, and the types of α, β, and γ chains 
that these ECM proteins consist of. 
Finally, further common and important ECM proteins are the tenascins and fibronectin. 
Their structures can be described as ‘beads-on-a-string’, since both consist of many small 
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domains in a row, connected by short linker regions. In addition, both are glycoproteins, and 
both consist to a large part of fibronectin type III domains.18 
Fibronectins (FN) are large dimeric proteins, about 230-270 kDa in size (reviewed in 
18,19). They can be subdivided into two groups: plasma-fibronectin (p-FN) and cellular-
fibronectin (c-FN). P-fibronectin is expressed and secreted by hepatocytes, whereas c-fibronectin 
can be expressed by many different cell types, like fibroblasts and chondrocytes. These FN 
variants are all derived from a single FN gene by alternative splicing of its primary transcript. 
FNs have functions as scaffold proteins, and influence cellular processes like migration and 
differentiation. During murine development, a homozygous interruption of the fibronectin gene 
(FN1) causes early embryonic lethality due to defects in the mesoderm, neural tube, and vascular 
system.20 FNs play an important role in the tissue repair process, like wound healing, but also 
have a pathological role in fibrosis.21 Mutations in FN1 also lead to disease like glomerulopathy 
with fibronectin deposits.22 
 
Figure 2.6 Tenascin-C hexabrachion23 
Rotary shadowing electron microscopy pictures of two mouse tenascin-C homo-hexamers. 
 
There are four tenascins described thus far: tenascin-C, tenascin-W, tenascin-R, and 
tenascin-X (reviewed in 18,24). The structure of all tenascins is very similar, starting with heptad 
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repeats at the N-terminus, EGF repeats, FN type III repeats, and finally a fibrinogen-like globular 
domain at the C-terminus. The heptad domain at the N-terminus is responsible for tenascins to 
assemble into homo-trimers which in the case of tenascin-C and tenascin.W can dimerize by 
disulfide bonds through their N-termini to homo-hexamers (Figure 2.6). The FN type III repeats 
and the fibrinogen globe seem to be responsible for most interactions with other proteins, like 
integrins, fibronectin, neurocan, and many more.18 Opposite to FN, which is a very good cell 
adhesion protein, tenascins seem to be anti-adhesive and influence the adhesion of cells to other 
ECM proteins25, thereby having an effect on processes like cell adhesion and migration26. 
Tenascins play a significant role in embryonic development. Indeed, both tenascins-C and -R. 
seem to be important in the development of the nervous system, though functions in adult tissues 
have also been described.24 The importance of tenascins in human is highlighted by mutations, 
which in case of mutations in tenascin-X can lead to Ehlers Danlos syndrome.27 
There are many other known ECM components which, together with the above 
mentioned proteins, make up the matrisome (reviewed in 28). The mammalian core matrisome 
includes all common ECM proteins and consists of approximately 300 proteins. Other examples 
of proteins that are part of the core matrisome are thrombospondin, elastin, fibrillin, etc. There 
are also a large number of ECM-affiliated and ECM-modifying proteins that are not included in 
the core matrisome.28 As discussed above the ECM plays a crucial role in many processes of a 
multicellular organism. Cells not only express and secrete the ECM proteins, but they also 
benefit from them in many vital processes. For this, transmembrane proteins of the cells need to 
be able to interact with the ECM proteins, as this is a way for cells to communicate with their 
environment, while the ECM influences the cells’ behavior.1 I will now outline how such an 
interaction between cells and the ECM can happen. 
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 There are several transmembrane proteins that direct cell-ECM adhesion and signaling. 
The largest and most well-known family are the integrins (reviewed in 29,30). Integrins are Ca2+-
dependent (or sometimes Mg2+-dependent) cell adhesion molecules (CAMs). So far, twenty-four 
integrins have been described. Each consists of a heterodimer composed of an α- and a β-subunit. 
The eighteen known α-subunits and eight known β-subunits give integrins their name, like α5β1 
consisting of α-subunit 5 and a β-subunit 1. In order to drive adhesion and signaling events 
between cells and the ECM, integrins need to connect the ECM to the cytoskeleton. The 
extracellular domain of integrins can bind many ECM proteins, like collagens and fibronectin. 
The intracellular domain is connected to the actin cytoskeleton via adapter proteins like talin, 
kindlins, and vinculin.30 Integrins do not simply connect the actin cytoskeleton to ECM proteins, 
but rather work in large protein complexes that are responsible for adhesion, outside-in, and 
inside-out signaling. This means that the ECM has an influence on the cell it interacts with, like 
causing a rearrangement of the cytoskeleton, and in turn the cell can also influence the ECM 
surrounding it. Some of these complexes are called focal adhesions (FAs), focal complexes and 
fibrillar adhesions (Figure 2.7). FAs are the best characterized of these complexes.30 One 
example of FAs are costameres, which are important complexes in skeletal muscles, as they 
connect the sarcomere and the sarcolemma and are involved in transferring force in muscles.31 
Integrin-mediated adhesion in FAs involves a large variety of proteins. Up to 100 different 
proteins can make up FAs, while the entire adhesome of integrins consists of about 160 
proteins.32 However, integrins are thought to initiate the assembly of the FA complex. Due to the 
relatively low affinity of these receptors to their partners, the integrins start to cluster, also 
increasing the adhesion strength of the cell to the ECM. Other proteins of the complex are then 
subsequently recruited, such that the nascent complex can mature into a FA.33 Since FAs have to 
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be dynamic, they can also be disassembled by ECM proteins like tenascins. Integrins do not 
strictly function in cell-ECM adhesion and signaling, but they are also involved in mediating 
cell-cell interactions.30,34  
 There are also non-integrin receptors for the ECM. One prominent example is 
dystroglycan (reviewed in 35). Dystroglycan consists of two glycoproteins, but is encoded by a 
single gene (DAG1). After expression of DAG1, the protein gets cleaved post-translationally to 
give rise to the two components α- and β-dystroglycan. The β-dystroglycan subunit contains the 
transmembrane domain of the receptor and connects to the actin cytoskeleton via linkers, while 
α-dystroglycan is responsible for interacting with ECM components like laminin, agrin, and 
perlecan.35 Another class is called discoidin domain receptors (DDR). DDRs are receptor 
tyrosine kinases that are activated by binding collagens and indirectly influence cell-ECM 
adhesion by influencing the activation of collagen-binding integrins.30 
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Figure 2.7 Cell-ECM adhesion contacts34 
Summary of several cell-ECM adhesion contacts and the key players involved. (A) Initial cell-
ECM contact is made by focal complexes, (B) which can mature into larger and more stables 
focal adhesions. (C) Fibrillar adhesions can then pull out certain components of the focal 
adhesion, which leads to a partial sorting. 
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2.2 Cell-cell adhesions 
 As mentioned above, cell-cell adhesion is another important process, especially in 
multicellular organisms. The adhesion can be temporary or permanent, depending on the tissue. 
In temporary adhesion, cells are typically not bound very tightly to each other. This process can 
be as short-term as leukocytes rolling along the endothelial cells of blood vessels to slow them 
down for leukocyte extravasation, where selectins on the surface of the endothelial cells bind 
their carbohydrate partners on the leukocytes.36 On the other hand, the adhesion can be more 
permanent, with the cells bound tightly to each other, for example to act as a barrier, as is the 
case in the intestinal epithelium, requiring so-called occluding junctions.1,37 These are two 
‘extreme’ examples of cell adhesion, while many more examples fall somewhere in between, 
like synapses. While the adhesion of the pre- and post-synaptic partners is also permanent, they 
are less stable than the cell junctions of the intestinal epithelial cells. Especially during neuronal 
development, it is thought that many more connections are formed than are finally needed in the 
adult. Hence, synapse adhesion has to be reversible when some of the neuronal connections are 
pruned in children and early adulthood, also called synaptic plasticity.38  
 One thing that all cell adhesion events have in common is that CAMs are required. CAMs 
can be subdivided into the following subgroups: cadherins, selectins, immunoglobulin (Ig) 
superfamily of proteins, and integrins (Figure 2.8). Just like integrins in cell-ECM adhesion, 
CAMs during cell-cell adhesion have a relatively low affinity for each other. Stronger forces 
between cells are accomplished by the clustering of CAMs in some areas of the membrane, 
where cells will attach. Once the cells adhere to each other through CAMs, can other proteins be 
recruited into complexes, called anchoring junctions, leading to a stronger attachment of cells 
(for more details, see below after CAMs).1,39 
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Figure 2.8 Major families of CAMs (adapted from 40,41) 
Overview of the four major families of CAMs. Cadherins and Ig-like CAMs undergo 
homophilic, selectins and integrins heterophilic interactions.  
 
 
Cadherins (CDH) are a large and well-studied glycoprotein family of CAMs (reviewed in 
42,43). They are Ca2+-dependent adhesion proteins, giving cadherins their name. Calcium 
stabilizes adjacent cadherin repeats, where increasing amounts of bound Ca2+ ions also increases 
the overall stiffness of the protein. A lack of Ca2+ leads to proteolytic degradation of the 
extracellular domain.42 Most cadherins are single-pass transmembrane domains, where the 
intracellular domain is linked to the actin cytoskeleton via catenins. The extracellular domains of 
cadherins mostly consist of extracellular cadherin (EC) repeats.42,43 Classical cadherins have five 
EC repeats, while non-classical cadherins can have additional EC repeats or other additional 
domains like EGF-like repeats.42 Cadherins are vital in embryonic development (and mature 
tissues), where different cadherins are responsible for the adhesion in specific tissues.43 Cell 
types expressing the same cadherins, like N-cadherin, will only assemble with each other, rather 
than with cells expressing another cadherin. This led to the conclusion that cadherins can help to 
form specific tissues during development due to homophilic, rather than heterophilic 
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interactions.42 Homophilic interactions take place when two or more of the same transmembrane 
proteins interact on apposing cells, while heterophilic interactions describe the interaction of 
different types of proteins. It has also been shown that cadherins can interact heterophilically or 
through a linker molecule, but this is less common.1 The founding members of the cadherin 
family were N-cadherin, E-cadherin, and P-cadherin.1 The letter indicates the tissue or cell type 
that the cadherin was originally identified in: N-cadherin (nerve cells), E-cadherin (epithelial 
cells), and P-cadherin (placenta).44 These cadherins are not exclusively expressed in the above-
mentioned tissues. N-cadherin is also expressed in the muscle, fibroblasts, etc.45 Next to the 
classical cadherins, there are also many non-classical cadherins found in vertebrates. One such 
example are the protocadherins, which are mainly expressed in the brain. They seem to be 
particularly important in the formation and stabilization of synapses.46 
 Another family of Ca2+-dependent glycoprotein CAMs are the selectins (reviewed in 
47,48). Selectins are type I transmembrane domain proteins with a small intracellular domain 
(ICD). The larger extracellular domain (ECD) consists of a lectin domain, EGF-like repeats, and 
between two and nine consensus repeats with homology to complement regulatory (CR) 
proteins, depending on the type of selectin.48 Other than the number of CR domains, is the ECD 
highly conserved between paralogs and orthologs, where paralogs are two or more genes that 
evolved from the same ancestral genes in the same organism by duplications of parts of the 
genome, and orthologs are genes in different species which evolved from the same ancestral 
gene. The lectin domains of the different selectins, which are responsible for the carbohydrate 
binding, can thus bind very similar sugar structures. These sugars are usually oligosaccharides on 
glycoproteins or glycolipids on other cells, meaning that selectins exclusively interact 
heterophilically.47 The transmembrane domain and ICDs are only conserved in orthologs, but not 
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in paralogs, which is how selectins gain their specific functions. There are three types of 
selectins, all of which are expressed on the surfaces of cells of the bloodstream. P-selectin is 
expressed in endothelial cells and platelets, L-selectin in monocytes, granulocytes, and most 
lymphocytes, and E-selectin is usually only expressed due to an induction by inflammatory 
cytokines.47,48 It was mentioned previously, as an example of a temporary cell-cell adhesion, that 
selectins are responsible for leukocyte capture and rolling along the endothelial cells lining the 
blood vessels, prior to leukocyte extravasation. As the leukocytes roll along the blood vessel, the 
selectin-carbohydrate interactions are quickly made and broken again in order to slow down the 
cell, which can also be described as a Velcro-like mechanism.49 This mechanism also shows how 
well different CAMs work perfectly in sync. Once selectins have slowed down the leukocyte, its 
integrins help stabilize the adhesion and allow it to extravasate from the blood stream into the 
tissue.36 
 Integrins have been mentioned extensively above, since they are mainly known as cell-
ECM receptors. However, as can be seen during leukocyte extravasation, integrins are also 
involved in heterophilic cell-cell interactions.36 A mutation in the β2-integrin gene results in 
leukocyte adhesion deficiency-I, also supporting the significance of integrins interacting 
heterophilically.41 These interactions include both, adhesion and signaling capabilities. Integrins 
are widely expressed in vertebrates and have many different functions, like aggregating 
keratinocytes or stabilizing synapses.30 
 Finally, there is the major Ca2+-independent family of CAMs, the Ig superfamily (IgSF) 
of proteins (reviewed in 50). IgSF is a very diverse family of proteins, currently including 765 
members, ranging from the neural cell adhesion molecule (N-CAM) to the major 
histocompatibility complex class I and II molecules. Members of the IgSF are typically single-
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pass type I transmembrane proteins, where the ECD has to contain at least one Ig-like domain. 
These Ig-like domains are mainly responsible for homophilic interactions. Heterophilic 
interactions with integrins or carbohydrates have also been described.50 Just like other CAMs, 
the ICD of IgSF members interacts with the cytoskeleton and can be involved in signaling. 
Probably the best-studied member of the IgSF is neural CAM (N-CAM). More than twenty 
isoforms of N-CAM have been identified thus far. N-CAM is expressed in a variety of cell types, 
but especially in subsets of neurons. Its most common function is to be involved in the 
development of the CNS, just like many other Ig-CAMs. These Ig-like proteins aid in axon 
guidance and synaptogenesis.39 Cadherins and IgSF members are often involved in the adhesion 
of the same cells. Since the interactions of Ig-CAMs are generally much weaker than those of 
cadherins, and mutations are less dramatic in embryonic development, it is likely that the 
members of the IgSF family are generally involved in the fine-tuning of cell-cell interactions. 
IgSF proteins also play a role in pathological processes.1 For example, several of the members 
like N-CAM, L1-type CAM, melanoma CAM, activated leukocyte CAM, etc. are involved in 
metastasis.50 
 There are several cell junctions that the CAMs help assemble: anchoring junctions, 
occluding junctions, and communicating junctions (Figure 2.1). Anchoring junctions mainly 
have a structural function by “anchoring” cells to each other or to the ECM, occluding junctions 
act as barriers across which water and small molecules can be selectively transported, and 
communicating junctions directly connect apposing cells to each other for mediating chemical or 
electrical signals. Not all CAMs are involved in assembling cell junctions, especially if they are 
not involved in selective adhesion. However, it is important that CAMs drive the adhesion of 
cells, before junction proteins are recruited, often becoming core proteins of the junction 
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themselves. Here, I will give a quick overview of cell junctions, by describing one example of 
each type of junction.1 
The adherens junction is an example of an anchoring junction (reviewed in 51,52). One of 
the central CAMs responsible for the formation of an adherens junction is E-cadherin. E-
cadherin forms homo-dimers that interact homophilically with an E-cadherin homodimer of the 
apposing cell. Other core proteins include β-catenin and p120-catenin. Catenins connect 
cadherins to the actin cytoskeleton. Adherens junctions have several functions, like the adhesion 
of two neighboring cells by connecting their cytoskeletons, especially when higher forces act on 
the tissue. In epithelial cells, the adherens junctions recruit actin filaments to form belt-like 
structures lining the plasma membranes of attached cells (Figure 2.9). Other functions include 
intracellular signaling and transcriptional regulation. For example, one of the core adherens 
proteins β-catenin is a transcriptional cofactor in Wnt signaling.53,54 Interestingly, while tight 
junction assembly requires adherens junctions, E-cadherin is not necessary for the stability of the 
tight junction.51 
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Figure 2.9 Adherens junctions1 
(A) Belt-like adherens junction between epithelial cells of the small intestine. (B) Basic structure 
of an adherens junction. 
 
In vertebrates, the occluding junction is called tight junction (reviewed in 51). Tight 
junctions are assembled by two transmembrane proteins, occludins and claudins (Figure 2.10). 
Intracellular zona occludens proteins link the junction to the actin cytoskeleton. The main site of 
assembly is the epithelium, where it helps create a barrier by tightly binding epithelial cells to 
each other, thus keeping contents on either side of the epithelium separate, like in the intestine. 
Certain nutrients need to be able to pass the epithelium. Hence, another property of the tight 
junction is that it is selectively permeable to ions, depending on which tissue the junction is 
located in. Tight junctions also create a barrier that the apical and basolateral receptors cannot 
diffuse onto either side. Since macromolecules cannot pass through the junctions, they must be 
transported through the cells. Glucose gets transported into the epithelial cells by apical surface 
receptors, and leaves the cell via receptors on the basolateral side. The nutrients can then enter 
small blood vessels that are embedded in the tissues.51 
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Figure 2.10 Tight junctions1 
(A) Tight junctions sealing two cells together by (B) interacting claudins and occludins. 
 
 There are several communication junctions that exist in vertebrates. Compared to the 
other two types of junctions, this junction’s main function is not structural, but rather in 
communication, by letting small molecules (less than 1 kDa)55 pass directly between cells.  An 
example of a communication junction is the gap junction (reviewed in 56). One type of gap 
junction is the electrical synapse, while chemical synapses are a different type of non-gap 
communication junction. Synapses will be discussed later in more detail.57 The channel of the 
gap junction, the connexon, is a hexamer and consists of connexin molecules (Figure 2.11). 
Connexins are a 21-member family of four-pass transmembrane proteins. Different combinations 
of connexins can form either homomeric or heteromeric connexons, but only certain 
combinations have been identified thus far. Connexons of two apposing cells need to line up to 
form a complete channel between the two cells. Both, homotypic and heterotypic intercellular 
channels exist. Gap junctions are assembled by neighboring cells in most tissues. The pore of the 
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channel is about 1.5 nm in size, which means that only ions and other small molecules, but no 
macromolecules can pass through, leading to an electrical and/or metabolic coupling. The close 
proximity of about 2 nm between two cells that is required for the gap junction to form, also 
keeps most other proteins from occupying that space.56 
 
Figure 2.11 Gap junctions56 
Six connexins form homomeric or heteromeric connexons, which can interact homo- or 
heterophilically on apposing cells to form a gap junction. 
 
 As can be seen in the previous two sections, both cell-ECM and cell-cell adhesion are 
vital in multicellular organisms. Vertebrate development would not be possible without these 
processes. In the developing CNS, cells migrate during early neural development to their 
appropriate locations, different parts of the brain develop during patterning and arealization, and 
neurons connect the different regions through axon guidance and synaptogenesis. One thing they 
have in common is that they all require cell-cell and/or cell-ECM interactions. 
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2.3 Early neural development 
 A lot is known about the mammalian CNS and its development. Since my projects were 
mainly set in a human context, I will focus on the human, or at least general mammalian, neural 
development when possible, starting with early embryonic development and how it gives rise to 
early neural progenitors. 
 After fertilization of the oocyte and once meiosis took place, it takes about another day 
until the first cleavage, which brings the embryo to the two-cell stage. Due to the asynchronous 
division of the blastomeres, the embryo reaches the ten-cell stage within four days, at which 
point it hatches from the zona pellucida. At the sixteen-cell stage, the morula has formed, with 
the outer part consisting of tightly bound cells, which will give rise to the trophectoderm. This 
becomes more apparent at the blastocyst stage, when the trophoblast is formed around a fluid-
filled cavity (blastocoel), also containing the inner cell mass (ICM) (Figure 2.12)35. The ICM 
now is in a pluripotent state (compared to the previously totipotent cell stages), i.e. its cells 
during gastrulation will give rise to the three germ layers that during further development will 
form the actual embryo, the embryo proper. The trophoblast is required for the blastocyst to 
implant, as it contacts the uterine epithelium, and it gives rise to the placenta that is required to 
nurture the developing embryo. This complete separation of the trophoblast and the ICM is the 
first of many differentiation events.58 By the time the embryo reaches E13, gastrulation starts. 
The ICM has segregated into two cell layers, consisting of the lower layer, the hypoblast (a.k.a. 
primitive or embryonic endoderm) and the upper layer, the epiblast (a.k.a. primitive or 
embryonic ectoderm). The hypoblast cells are released from the ICM and become part of 
extraembryonic tissue by lining the blastocoel. At this time, the epiblast starts to form the three 
primordial germ layers: mesoderm, endoderm, and ectoderm. Gastrulation starts by primitive 
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streak formation and individual epiblast cells migrating through it, and towards the rostral end of 
the embryo, forming two new layers. The lower layer becomes the definitive endoderm, 
replacing the hypoblast, and the intermediate layer becomes the mesoderm. The endoderm gives 
rise to tissues like the gut and respiratory system, and the mesoderm forms tissues like muscle, 
bone and cartilage.59 
 
Figure 2.12 Early human embryonic development60 
Developing human embryo, from fertilization to the gastrula stage. 
 
 
 Most significant to neural development at this point is the ectodermal layer, which forms 
into epidermal-ectodermal and neurectodermal progenitors. The epidermal-ectodermal lineage 
will form tissues like skin, nails and sweat glands, while neurectodermal cells are the neural 
progenitors that give rise to the CNS. These neural progenitors are now lining the rostral-caudal 
midline (neural plate) and start forming their first neural structure around E20-E27, the neural 
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tube. Formation of the tube starts by two ridges emerging on the neural plate, with the neural 
progenitors located between them. The ridges then fold up and inward, and fuse to each other to 
form a hollow tube. Inside, the hollow tube is lined by a single-cell layer of neural progenitors. 
From now on, the CNS formation becomes more complex, with the rostral end of the neural tube 
forming the brain and the caudal end developing into the hindbrain and spinal column.59,61 
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2.4 Patterning of the brain 
 Once the primitive neural structures have been formed, they have to develop further into 
different parts of the CNS including the complex organization of the brain. While patterning of 
the CNS starts in the embryo, at this point still quite primitive, it goes on for several years. Brain 
patterning starts by three primary brain vesicles (neuromeres) developing at the anterior part of 
the neural tube, just before it closes. These primary neuromeres are called prosencephalon 
(which itself is divided into the telencephalon and diencephalon), mesencephalon, and 
rhomboencephalon, and subsequently divide into secondary neuromeres during different stages 
of development (Figure 2.13). This division takes place along the rostral-caudal axis. The 
vesicles of the telencephalon start to take the form of the brain hemispheres by eight weeks of 
gestation, which is also the end of the embryonic period. Other parts of the primitive CNS, like 
the spinal column, hindbrain, and sensorimotor regions of the neocortex are starting to be 
specified as well at this point.61 
Organization and arealization of the brain is driven by a complicated network of 
transcription factors, CAMs and secreted proteins. Homeobox (HOX) proteins for example are 
often expressed in gradients during development, specifying the anteroposterior order of 
segments in the hindbrain and spinal cord.62 However, the neocortex is the best-studied example 
in brain patterning. The cerebral cortex is the largest and most complex part of the brain and is 
formed from the dorsal telencephalon. The neocortex makes up the largest part of the cerebral 
cortex, and consists of six layers (I-VI, numbered from the outermost to the innermost layer). 
Functions of the neocortex include the processing of visual and auditory information, and the 
voluntary movement of body parts.63  
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Figure 2.13 Lateral view of the developing brain64 
Several stages of early human brain development. (A) and (B) show the primary neuromeres in 
brain patterning, which (C) and (D) turn into secondary neuromeres. (E) At 50 days, the brain 
has started to develop from the vesicles of the telencephalon.  
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The signaling molecules that regulate transcription factors responsible for patterning of 
the neocortex, are secreted by so-called patterning centers. Some of the major patterning centers 
are called commissural plate, cortical hem, and antihem, and secrete factors such as members of 
the FGF, WNT, BMP, and NRG families of proteins. SHH is secreted by a patterning center of 
the ventral domain, but only indirectly affects arealization of the neocortex. Four transcription 
factors directly involved in the patterning of the neocortex have been identified in cortical 
progenitors thus far: COUP-TFI, EMX2, PAX6, and SP8.63 
 
Figure 2.14 Patterning of the neocortex65 
The four transcription factors expressed in gradients during the arealization of the neocortex, 
responsible for specifying the anterior (A) – posterior (P) and lateral (L) – medial (M) axes. 
 
 
 
COUP-TFI, EMX2, PAX6, and SP8 are expressed as gradients and specify the 
arealization of the anterior-posterior and lateral-medial cortical axes (Figure 2.14). Specifically 
altering the expression levels of any of these transcription factors also changes the proportion 
and position of the different cortical areas. When overexpressing Emx2 in the neocortex, it 
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causes the size of the primary sensory and frontal/motor cortical areas to change, without 
increasing or decreasing the overall size of the cortex. Further, the transcription factors 
specifying the different regions of the neocortex are highly concentration dependent, also seen by 
the gradient patterns of expression. The “Cooperative Concentration Model” states that all four 
transcription factors are expressed across all cortical progenitors, but differing levels of 
expression are responsible for generating the regions of the neocortex.66 
The development of the brain lasts throughout the embryonic and fetal periods, and into 
the post-natal period. During this time, the brain is still malleable and can be influenced by 
different inputs and experiences.59 For example, the sizes of primary cortical areas can vary 
between two- and three-fold, across individuals of a normal population. The overall volume of 
the cortex only varies around 30%. Responsible cues or inputs have not been identified yet.66 
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2.5 Axon guidance and synaptogenesis 
 Neurons and their processes connect the different areas of the brain and make up a 
significant part of the peripheral nervous system. They are responsible for sending 
electrochemical signals within the entire body in milliseconds. Neurons consist of a cell body, a 
single axon, and several branched dendrites. Axons can be as short as 1 mm and reach a length of 
up to one meter and may branch hundreds of times, making neurons very unique cell types. 
Different types of glial cells support neurons structurally, provide them with nutrients, and help 
form insulating myelin sheaths around their axons. In most cases, the dendrites and axons of 
different neurons are connected and communicate with each other via synapses.1 The cell bodies 
of neurons start to appear around E42, by asymmetric division of the neural progenitors. 
Previous symmetric division of neural progenitors led to two subsequent progenitor cells, 
whereas asymmetric division now leads to one neuron and one neural progenitor. Regions of the 
brain that contain neuronal cell bodies give it a grey color, thus naming it grey matter. Fibrous 
parts of the brain that lack these cell bodies are called white matter. The axons then start to grow 
out to connect with their dendritic partners. It is estimated that more than 100 billion neurons 
exist in the human brain, each making an average of 1000 connections. Most of these 
connections are established by mid-gestation, but neuronal development is not completed until 
young adulthood, or arguably not completed for the entirety of the lifetime. This leads to a very 
complicated, but perfectly organized neuronal network. To make the connections between 
neurons, axons have to “find” the right path in a process called axon pathfinding or axon 
guidance. Once the axon has reached its proper target, a synapse is formed with the dendrite of 
another neuron, which is called synaptogenesis.59 
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 Axon pathfinding was first mentioned more than a century ago by Ramόn y Cajal, who 
proposed that the axons are guided to their proper targets by a set of long-range chemical 
attractants, secreted by the target cells. This was a remarkable observation, even though axon 
guidance is a bit more complicated as the past decades of research have shown. He also gave the 
club-like structure at the tip of the axon its name, the growth cone.67 The growth cone is a highly 
motile structure that extends the axon and determines the direction of axon guidance, by 
receiving signals through its receptors. A significant part of the growth cone is the 
lamellipodium, which consists of an F-actin network and is considered to drive the extension of 
stable microtubules in the axon. Small protrusions of F-actin bundles, called filopodia, 
continuously extend and retract from the lamellipodium, “searching” for appropriate cues. 
Attractive or repulsive signals are recognized by the aforementioned receptors in the membranes 
of the filopodia, the growth cone undergoes rapid cytoskeletal rearrangement and then turns 
where the guidance cues direct it.68 These signals involve direct interactions of receptors of the 
growth cone with receptors of other cells or ECM proteins. Many of the guidance cues can act as 
both, an attraction or a repulsion signal, depending on the neuron. A molecule may even attract 
and later repulse the same growth cone at different points of its path. There are four main classes 
of proteins and their receptors that are involved in guiding axons: netrins bind to deleted in 
colorectal cancer receptors, slit binds to roundabout, semaphorins bind to plexins, and ephrins 
(EFN) bind to ephrin receptors (EPH) (Figure 2.15). Other proteins that had previously been 
identified as potential candidates, like N-CAMs and integrins, are more involved in axon 
outgrowth than its guidance.67,69 
 Once the axon has reached its target dendrite, a synapse has to form, in a process called 
synaptogenesis. As mentioned previously, synapses are communicating junctions, which are 
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involved in sending electrochemical signals from a presynaptic neuron to its postsynaptic 
partner. Unlike other communication junctions, like gap junctions (e.g. electrical synapses), 
chemical synapses are very asymmetric, while its basic functions are the same. Synapses are also 
involved in physically coupling two cells to each other, as well as in intracellular membrane 
trafficking and communication between the two cells. The main communication between 
neurons is via chemical neurotransmitters that are released in vesicles from the membrane of the 
pre-synaptic neuron, move across the small gap and are recognized by receptors of the post-
synaptic neuron.1,57 
 
Figure 2.15 Axon guidance (adapted from 70) 
Several cues guide the axon towards its target, either in an attractive or a repulsive manner. 
Short-range cues are membrane-bound, and long-range cues are secreted. Guidance molecules 
are recognized by receptors on the growth cone. 
 
Synaptogenesis is a very complex process, as there are over 100 billion neurons in the 
brain, forming an average of 1000 synapses each. It has been proposed that synapses do not form 
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between two specific neurons, but between two classes of neurons, putting an emphasis on the 
total number of formed synapses. This slightly reduces the complexity, and may also explain the 
significance of pruning during development, if an unspecified number of synapses are formed 
between classes of neurons.71 Synaptic density is at its highest in humans around the age of five, 
and synaptic pruning is thought to continue until the age of thirty.38 The specificity of synapse 
formation is determined by the axon finding its target dendrite and getting in close proximity of 
it, before synapse cell adhesion can start. Once the growth cone enters the neuropil, CAMs start 
forming the synapse. There are several proteins involved, like CDHs, N-CAMs, EFNs/EPHs, and 
neurexins/neuroligins. The specific roles of these CAMs in synapses have not yet been 
identified, however it is proposed that they are involved in the formation and mechanical 
stability of synapses, as well as trans-synaptic signaling. Their involvement in the specificity of 
the formed synapse is unlikely.71 Other protein families involved in axon guidance and 
synaptogenesis, like the teneurins, are only starting to be investigated in more detail in recent 
years.72 
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2.6 Teneurin overview and structure 
 Teneurins were originally discovered in Drosophila by two independent laboratories. The 
first approach identified two teneurin paralogs while screening a Drosophila expression library 
for tenascin-C homologs in arthropods, based on its EGF-like repeats.73,74 The two newly 
discovered proteins received the names tenascin-like accessory (ten-a), and tenascin-like major 
(ten-m). Both names are still in use today, but only in a Drosophila context. Further studies 
showed that ten-a and ten-m differed structurally and functionally from tenascins, with only the 
EGF-like repeats in common. The other approach identified ten-m, when screening for 
phosphotyrosine-containing proteins in Drosophila. It was given the name odd Oz (odz), due to 
mutations in embryos showing an “oddless” pair-rule phenotype.75 It was only discovered 
recently that the pair-rule phenotype was an artefact, due to a problem with the balancer 
chromosome in the mutant embryos.76 The now commonly used name ‘teneurin’ was proposed 
by the original discoverers of the protein family, and stems from its historic name in Drosophila, 
and its neuronal context, which will be discussed later in more detail.77 
Recent papers that focus on the evolution of teneurins, have identified orthologs across 
phyla, even in eukaryotic unicellular organisms, such as the choanoflagellate Monosiga 
brevicollis (Figure 2.15).78 Teneurins have also been studied in C. elegans, in which a long 
(TEN-1L) and a short isoform (TEN-1S) of the same gene, but no paralogs, are expressed.79 
Vertebrate orthologs of teneurins were first identified in the mouse.80 Most vertebrates express 
four paralogs, called teneurins 1-4 (Tenm1-4 in most vertebrates, TENM1-4 in humans).81,82 
Zebrafish are an exception with five paralogs, teneurins-1, -2A/B, -3, and -4. 
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 Teneurins are a family of single-span type II (amino-terminus is in the cytosol and 
carboxy-terminus is extracellular) transmembrane glycoproteins that are well-conserved across 
phyla (basic structure of teneurins summarized in Figure 2.16). This family of proteins consists 
of a relatively small N-terminal ICD (ca. 45 kDa), followed by a single transmembrane domain, 
and a much larger C-terminal ECD (ca. 260 kDa). The sequence of the large ECD is very well-
conserved between ortho- and paralogs across phyla, unlike the ICD.83 The overall sequence 
identity in vertebrates is between 60% (orthologs) and 98% (paralogs), and between 33% and 
41% between vertebrate and Drosophila or C. elegans teneurins. The vertebrate ICDs have a 
sequence similarity of 50-60% (paralogs) and 70% (orthologs). Vertebrate teneurin ICDs have 
several features: the polyproline-rich region can bind SH3-domain containing proteins (also 
found in invertebrate ICDs) such as CAP/Ponsin, several putative phosphorylation sites and an 
EF-hand like domain that can bind Ca2+ ions.84,85 Some ICDs also contain predicted nuclear 
localization signals (NLS). The presence of an NLS was confirmed in chicken teneurin-1, by 
site-directed mutagenesis.86 The C. elegans isoforms of TEN-1 only differ in their ICDs, the 
longer isoform containing a predicted NLS, while the shorter isoform does not.79 Adjacent to the 
ICD is a transmembrane domain, followed by a short linker region and EGF-like repeats of the 
ECD.77 There are eight EGF-like repeats, which are responsible for dimerization of teneurins. 
Most repeats contain an even number of cysteines that form disulfide bridges with each other, 
except in repeats two and five. Instead of one of the cysteines in each of the two repeats, there is 
a tyrosine in its place. Hence, two neighboring teneurin molecules can form disulfide bonds in 
repeats two and five, and thus dimerize.81,87 The following NHL-repeat domain is a predicted 
beta-propeller and is involved in protein-protein interactions.81,88 Teneurins are known to interact 
with proteins on apposing cells and with ECM proteins.83,88,89 In teneurins-1 and -2, the NHL-
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repeat domain is responsible for homophilic, rather than heterophilic interactions.88,90 Other 
studies have shown a heterophilic interaction between teneurins and latrophilins.89,91 The 
subsequent 26 YD-repeats are unique to teneurins as non-bacterial proteins82, followed by a short 
peptide resembling the corticotrophin releasing factor (CRF), the teneurin c-terminal associated 
peptide (TCAP).92 YD-repeats in bacteria are part of cell wall proteins in gram-negative bacteria 
and have a strong affinity for carbohydrate-binding; their functions in teneurins are mainly 
unknown.82 Previous studies suggest that TCAP has neuromodulatory activity.93 
 
Figure 2.16 General teneurin structure (adapted from 94) 
Overview of the basic domain organization. ICD = intracellular domain; ECD = extracellular 
domain; N = amino-terminus; C = carboxy-terminus; Y = tyrosine residue; EF = EF-hand-like 
motif; PP = polypoline-rich motif; TM = transmembrane domain. 
 
 There are several predicted furin-cleavage sites in the teneurin ECD. The teneurin 
molecule could thus be processed into several individual domains, i.e. shedding the entire ECD, 
and the TCAP into the extracellular milieu.94 Cleavage of the ECD at the membrane is one of the 
requirements for releasing the ICD via regulated intramembrane proteolysis (RIP).95 Proteases 
for teneurin RIP have not been identified yet. Signal peptide peptidase or site-2 protease are 
likely candidates, as they are involved in the processing of type II transmembrane proteins.94 
Several studies have shown the release and subsequent translocation of the ICD into the 
nucleus.84,86,96 
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Table 2.1 Summary of teneurin nomenclature and expression during development 
Includes only proteins with known expression patterns; adapted from 97  
Species Name Synonyms Expression pattern 
Caenorhabitis 
elegans 
Ten-1L79  Somatic gonad79,98, vulva, subset of neurons, 
gut, some hypodermal and muscle cells79, 
pharyngeal cells98,99, intestine cells99 
Ten-1S79 Subset of neurons, some hypodermal cells79,99 
Drosophila 
melanogaster 
Ten-m74,83 Odz75,100 Odd-numbered parasegments74,75, subset of 
neurons74,101,102, tracheal system, cardiac cells, 
lymph glands, muscle attachment sites74, 
morphogenetic furrow83,100, wing pouch, leg 
and antennal discs100, motor neuron76 
Ten-a73,103  CNS73,103,104, eye, muscle attachment sites73,103 
Danio rerio Teneurin-3 Ten-m3105 Developing brain, somites, notochord, 
pharyngeal arches105, subset of neurons106 
Teneurin-4 Ten-m4105 Developing brain, spinal cord105 
Gallus gallus 
domesticus 
Teneurin-177,83  Developing CNS and eye77,83,86,107, limb 
buds107 
Teneurin-277,108 Developing brain and eye77,86,107, AER of limb 
buds, tendon primordia, pharyngeal arches, 
heart, somites, neural tube, craniofacial 
mesenchyme108 
Teneurin-3107 Developing CNS, central retina, limb bud107 
Teneurin-4107,109 Developing CNS, ZPA of limb buds, 
pharyngeal arches109, heart, lung bud107 
Rattus rattus Teneurin-2 Neurestin110,111, 
lasso91 
Developing and adult CNS110,111, somites110 
Mus musculus Teneurin-1 Ten-m181, 
odz1112,113, ten-
m/odz1114 
Developing and adult CNS81,113,114, eye, 
smooth muscle cells in lungs, kidney 
glomeruli, adult testes81 
Teneurin-2 Ten-m281, 
odz1115, odz2112, 
ten-m/odz2114 
Developing and adult CNS113,114, developing 
eye116 
Teneurin-3 Ten-m381, 
odz3112,113, ten-
m/odz3114 
Developing and adult brain113-115, developing 
eye112,117-119, spinal cord, notochord, 
craniofacial mesenchyme, tongue, dermis, 
saccule, developing limb, periosterum112, 
cartilage120 
Teneurin-4 Ten-m481, 
odz4112,113,121, ten-
m/odz4114, 
Doc480,112,115 
Developing and adult brain80,113-115,122, 
developing eye, somites, spinal chord, trachea, 
nasal epithelium, saccule, joints, adipose 
tissue, tail bud and limbs114, cartilage123, 
embryonic mesoderm124 
Macropus 
eugenii 
Teneurin-3 Ten-m3125 Developing visual system125,126 
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2.7 Teneurin expression and functions 
 One of the key sites of expression of teneurins is the (developing) CNS, especially in 
well-defined subpopulations of neurons. Expression of teneurins is also found in many non-
neural tissues and has been investigated in several animal models, ranging from Drosophila to 
the mouse (Table 2.1).  
Several developmental functions involving ten-a and ten-m have been identified in 
Drosophila. Loss-of-function of ten-a and ten-m lead to eye defects, like photoreceptor loss.127 
Ten-m and filamin physically interact to affect the axon guidance of motor neurons in 
Drosophila.76 Heterophilic interaction of ten-a in the pre-synaptic and ten-m in the post-synaptic 
neuron are required for synaptic organization in the neuromuscular junction.102 Guidance and 
connectivity of olfactory receptor neurons with projection neurons in an olfactory map is driven 
by homophilic interactions of ten-a and ten-m.101 Finally, ten-a is one of the genes involved in 
central complex formation, the part of the brain involved in several processes like visual and 
olfactory memory.104 
 Expression of the two ten-1 isoforms in C. elegans had very complex and distinct 
patterns, not only in developing larvae, but also in adult worms. Patterns of expression are not 
restricted to the developing nervous system, but also include the gut, gonads, and some 
hypodermal cells. Both, an RNAi knockdown and the knockout (KO) of the ten-1 gene in C. 
elegans had drastic effects on some larvae, which included protusion of the vulva, defects in the 
CNS and disintegration of the somatic gonad.79 Further studies show the expression and 
involvement of ten-1 in somatic precursors of the gonad, which also seem important for the 
integrity of the pharyngeal basement membrane.98 Another RNAi approach identified phy-1, the 
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catalytic domain of collagen prolyl 4-hydroxylase as an interaction partner of ten-1. Double-
mutants embryos of ten-1 and phy-1 disrupted the integrity of the basement membrane and 
showed epidermal defects.128 
 In the zebrafish, only expression patterns of Ten-m3 and Ten-m4 have been described 
during development of the embryo. Ten-m4 has a faint expression pattern during gastrulation, 
while no Ten-m3 expression can be detected. During later stages of development, Ten-m3 and 
Ten-m4 expression was detected in the brain, while Ten-m3 was also expressed in somites, 
notochord and the pharyngeal arches. The two genes showed complimentary expression patterns 
during different stages of development of the forebrain and midbrain, which is often 
characteristic for teneurins.105 Another study showed Ten-m3 expression in a subset of 
developing neurons, especially of the zebrafish visual system.106 
 Teneurins have also been studied in the avian model, Gallus gallus domesticus. As 
expected, teneurins have their strongest expression in the developing chick CNS. Teneurin-177,83, 
as well as teneurin-277, are expressed in subsets of neurons in the developing visual system. This 
distinct and largely non-overlapping expression of teneurins-1 and -2 in the visual system is 
especially found in the tectofugal and thalamofugal pathways, respectively.90 Complementary 
patterns of teneurin-1 and -2 expression have also been described for other parts of the 
developing chick CNS, like the retina, olfactory bulb and cerebellum.86 During different stages 
of development, teneurin-4 is first expressed in bundles of axons in the nasal retina, and later in 
the temporal ganglion cell layer.107 Teneurin-2 and-4 are both expressed in non-neural tissues, 
like the developing limbs.107-109 In vitro, teneurin-2 overexpression leads to an increased number 
of filopodia, and enlarged growth cones.77  
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 The first teneurin discovered in mice, and vertebrates in general, was teneurin-4, in a 
screen to identify genes up-regulated by CHOP. It was originally called DOC4, or “downstream 
of CHOP 4”.80 Interestingly, the micro-RNA miR-708 is located in a teneurin-4 intron, and is co-
regulated by CHOP, together with ten-m4, to control the expression of rhodopsin.129 Expression 
studies in mice focused mostly on patterns in neural development, where teneurins are widely 
expressed.81,112 Other sites of expression included the trachea and mesodermally-derived tissues 
of the developing embryo.112 One very complete study of teneurins-1-4 utilized 
immunochemistry and in situ hybridization, and described the predominantly distinct yet 
overlapping expression patterns in the developing and adult nervous systems.114 Two studies 
describe non-neural functions of teneurin-4 in the gastrulation of the mouse embryo, where it 
establishes the anterior-posterior axis and is important for mesoderm-derived tissues. The 
teneurin-4 mutation led to an arrest of the embryo prior to E6.5.121,124 Teneurin-4 also plays a 
role in oligodendrocyte differentiation and myelination of small-diameter axons, by activating 
focal adhesion kinase (FAK) through phosphorylation.130 The same group reported that the 
activation of FAK by teneurin-4 is also responsible for neurite outgrowth and cellular protrusion 
formation in vitro.122 Other studies have also investigated teneurins in neurite outgrowth.83,90,131 
Only recently have knockout mouse models of teneurins been described. Ten-m2116 and ten-
m3117 KO mice have given some important insights into the functions of teneurins during 
development. The effects were not as drastic, as may have been expected, especially in 
comparison to the C. elegans KOs. However, since four teneurins are expressed in mice, it is 
possible that redundant expression or up-regulation of another paralog rescues some of the 
phenotypes. Particularly the developing visual system of the mouse has been investigated in the 
KO mice. Most importantly, ten-m2 and 3 both regulate ipsilateral projections and are thus 
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critical for binocular mapping.116,117,119 Another non-neural function in mice involves teneurins 
in chondrogenesis. Ten-m3 acts as a positive regulatory factor in the early stage of chondrogenic 
differentiation120, while ten-m4 suppresses the differentiation of chondrocytes.123 
 Teneurins have also been studied in two other vertebrate models, namely in rat and the 
marsupial wallaby. Neurestin, which corresponds to teneurin-2, is the only ortholog described in 
the rat thus far. It was cloned from the olfactory bulb, and its expression was described by 
Northern blot and in situ hybridization. As expected from expression studies in other vertebrates, 
neurestin/teneurin-2 is also mainly expressed in the developing and adult brain of rats, like the 
neocortex or the olfactory bulb.111 In the other vertebrate model, the marsupial wallaby, 
Macropus eugenii the authors compared the role of ten-m3 in binocular vision in the mouse and 
the wallaby. Ten-m3 affects ipsilateral projections in both animal models, confirming a role in 
binocular mapping.117,119,125,126 
Teneurins were the first transmembrane proteins, identified as pair-rule genes. This was 
very unusual, because all pair-rule genes described to date were transcription factors.74,75,81 Later 
it was shown that teneurins can be cleaved at the membrane and translocate to the nucleus, 
explaining the potential link to transcriptional regulation.84,86,96 While the evidence of teneurins 
being pair-rule genes was later refuted, it paved the way towards investigating the ICD in more 
detail.76 Since none of the ICDs contain an intrinsic DNA binding sequence, interaction partners 
are required to regulate transcription. Studies with ICDs have mainly focused on teneurins-1 and 
-2. Interaction partners of the TEN1-ICD have been identified by several yeast-2 hybrid (Y2H) 
screens, initially in an avian context. The ICD of chicken teneurin-1 can bind to CAP/Ponsin, 
linking it to the cytoskeleton. It also translocates to the nucleus in vitro, where it interacts with 
MBD1, a transcriptional repressor with DNA-binding activity.84 The chicken teneurin-2 ICD 
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affects Zic-mediated repression and localizes to PML bodies in the nucleus, so-called 
transcriptional hotspots (Figure 2.17).96 
 
Figure 2.17 Current model of teneurin molecular function (adapted from 94) 
Teneurins dimerize through the EGF repeats. The ICD can link to the cytoskeleton via 
CAP/Ponsin binding. 1. Once the ECDs interact homophilically, they get cleaved and released 
into the extracellular milieu. 2. The ICD gets processed by RIP and translocates to the nucleus. 
3. In the nucleus, the ICD interacts with transcriptional regulators like Zic and MBD1. 
 
Several ligands and molecular functions have also been identified for the teneurin ECDs. 
As previously mentioned, the ECDs of teneurins-1 and -2 can interact homophilically.88,90 Lasso, 
a splice-variant of teneurin-2, was identified in the rat brain. Pre-synaptic latrophilin 1 can 
specifically bind post-synaptic lasso, to form a trans-synaptic complex.91 Going more in-depth 
into this interaction than the previous study, another group discusses the combinations of 
teneurins and latrophilins in trans-synaptic binding, and suggests a function in synapse formation 
and maintenance.89 
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Figure 2.18 Ten-m1-4 homodimers87 
Rotary shadowing electron microscopic images of purified recombinant ten-m1-4 extracellular 
domains as homodimers.  
 
It has recently been proposed that the NHL domain, YD-repeats and the adjacent C-
terminal peptide of the teneurin ECDs may have a novel function in eukaryotes that would also 
put previously identified processes of TCAP function into question. Sequence similarity of this 
region with ABC toxins of the gram-negative bacterium Yersinia entomophaga is striking. ABC 
toxins are generally secreted to target other bacterial or eukaryotic cells. Three proteins (A, B, C) 
need to assemble for the complex to be toxic. The complex functions either by the A protein 
binding directly to the target cell, or by forming a pore. The C-terminal region of the C protein is 
the cytotoxic component. Thus it is possible that the YD-repeats also form an encapsulation 
device that contains the C-terminal toxic peptide, which is subsequently delivered to the target 
cell. Potential initiators, delivery systems, and functions would have to be investigated in future 
studies.132,133 Transmission electron microscope pictures of murine teneurin dimers show 
‘lollipop-like’ structures, which resemble BC toxin dimers (Figure 2.18).81 The fact that 
teneurins are ancient proteins and most likely evolved from a bacterial protein through horizontal 
gene transfer may further support this hypothesis.78 
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Little is known about the regulation of teneurin genes. There is evidence that FGF8 
regulates teneurin-2 expression in avian limb buds.108 Another study suggested teneurins to be 
potential target genes of Emx2 and Pax6 in the mouse cortex.113 Human TEN-M1 was later 
confirmed as a direct target gene of EMX2.134 In Drosophila, ten-m may be regulated by 
transcription factors Abrupt and Knot.135 
 In summary, teneurins are a family of proteins, involved in the development of the CNS, 
and some other (adult) tissues. Evidence from the studies above strongly implicate teneurins to 
have important functions in axon guidance and synaptogenesis. Other functions may include an 
involvement in the integrity of the basement membrane and chondrogenesis. However, a lot is 
still left to be learned about teneurins. For example, most molecular mechanisms of function are 
still unknown.  
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2.8 Teneurins in disease 
 The teneurin family of proteins has been implicated in several diseases. One of these 
diseases has a confirmed link, a null mutation in teneurin-3 causing microphthalmia in 
humans.136 Teneurin-1 may be one of the proteins involved in X-linked mental retardation 
(XLMR). TEN-M1 is located on chromosome Xq25, an area of the genome to which several 
XLMR-related genes have been mapped. Interestingly, some of the symptoms of XLMR include 
visual impairment and motor sensory neuropathy, which would fit into the context of teneurin 
function in CNS development.83 
 Some of the binding partners of teneurin ICDs discussed above, may also imply teneurins 
in disease. The ICD of teneurin-1 directly interacts with MBD1, a protein that is associated with 
autism.84 Mutations in zic1, an interaction partner of the teneurin-2 ICD, are linked with Dandy-
Walker syndrome.96 
 Teneurins have also been implicated in bipolar disorder. A large-scale study of 
individuals with bipolar disease compared to a control group revealed a new susceptibility locus 
of bipolar disease near the TEN-M4 gene.137 
 A recent review discusses expression levels of teneurins in different types of tumors and 
infers a function in human malignancy. The authors used a bioinformatics approach, only 
focusing on teneurins-2 and -4, which may also be due to a lack of the data that is currently 
available. Both show altered expression levels in a variety of tumors, like TEN-M2 in 
hepatocellular carcinomas, and TEN-M4 in brain tumors. It remains to be seen, which 
mechanisms teneurins are involved in and whether they are oncogenes, tumor suppressors or 
neither.138 
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3. Aim of the thesis 
 Teneurins are a well-conserved family of proteins that are expressed in many tissues, but 
especially in the developing CNS of C. elegans, Drosophila, and vertebrates. An interesting 
feature of teneurins are the YD repeats located near the C-terminal end of the ECD. YD repeats 
are unique to eukaryotic proteins, since they are usually expressed in bacterial cell wall proteins 
of gram-negative bacteria. It not only raises the question of how teneurins acquired this 
particular domain, but also how this protein family evolved (Chapter 4.1). 
 The teneurin ICDs are cleaved at the membrane and released to translocate to the 
nucleus. The transcriptional regulation capabilities of the teneurin ICDs are of particular interest. 
Previous studies have shown that the teneurin-1 ICD interacts with transcriptional repressor 
MBD1, and the teneurin-2 ICD affects Zic-mediated repression. However, little is known about 
the molecular mechanisms of teneurin function. We performed two types of unbiased screens, 
(1) yeast-2 hybrid screen and (2) whole transcriptome analyses, to gain new insight into the 
functions of teneurin ICDs (Chapter 4.2). 
 An elegant study utilized the cutting-edge technique AFM-SCFS to determine that 
chicken teneurins-1 and -2 interact homophilically rather than heterophilically. Domain-
swapping experiments between both teneurins showed that the NHL repeat domain is responsible 
for the specificity of this interaction. Interestingly, NHL repeat domains are predicted beta-
propellers. Beta-propellers have previously been implicated in protein-protein interactions, but 
not in determining the specificity of homophilic versus heterophilic interactions. Hence, we were 
interested in resolving the structure of the NHL repeat domains of teneurins (Chapter 5). 
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4. Publications 
 
 
 
4.1 Phylogenetic Analysis of the Teneurins: Conserved Features and 
Premetazoan Ancestry 
 
Richard P. Tucker, Jan Beckmann, Nathaniel T. Leachman, Jonas Schöler, 
and Ruth Chiquet-Ehrismann 
 
Mol Biol Evol (2012) 29 (3): 1019-1029 
First published online: October 31, 2011 
 
 
 
 
 
My contributions to this paper: 
For this study, I cloned and described the splice variants of the human teneurin intracellular 
domains and performed some initial sequence alignments. Further, I gave input to the 
manuscript. 
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4.2 The intracellular domain of Teneurin-1 influences MITF-dependent 
transcription by HINT1 binding 
 
Jonas Schöler, Jacqueline Ferralli, Stéphane Thiry, 
and Ruth Chiquet-Ehrismann 
 
 
 
MS ID#: JBC/2014/615922 
In Revision 
 
 
 
 
My contribution to this paper: 
For this study, I cloned the constructs and established the stable cell lines. I performed the 
Western Blot, all real-time Q-PCR experiments and prepared the total RNA for the whole 
transcriptome analyses. Further, I was involved in the planning and analysis of all other 
experiments. I wrote the first and final versions of the manuscript, with the input of the co-
authors. Finally, I revised the manuscript and performed the necessary revision experiments. 
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5. Unpublished work 
5.1 Methods and Materials 
 Together with the Protein Structure Facility (PSF) at the FMI, we have set up a protocol 
for the expression and purification of the chicken teneurin-1 (cten-1) and -2 (cten-2) NHL repeat 
domains in a bacterial system. For the general bacterial expression and purification protocols 
established by the PSF, please refer to Appendix C. 
 
5.1.1 Cloning and testing of the cten-1 and -2 NHL repeat domain constructs 
 All NHL repeat domain constructs were cloned from full length cten-1 and -2 constructs. 
Full length constructs were provided by Jan Beckmann, a former PhD student in the lab; 
preparation of the constructs is described in 88. NHL repeat domain constructs were prepared 
with specific primers by in-fusion cloning (Clontech) into the pOPINF bacterial expression 
vector (Addgene) (Table 5.1). 
Table 5.1 Primers used for in-fusion cloning of constructs 
Primer Name Primer Sequence 
pOPINF cten1 for1112 AAGTTCTGTTTCAGGGCCCGAACAAACACCATGTA
TTAAATCCACAAAGTGGAATTG 
pOPINF cten1 for1164 AAGTTCTGTTTCAGGGCCCGAACAGCAAACTCTTT
GCCCCAGTTGCTC 
pOPINF cten1 rev1510 ATGGTCTAGAAAGCTTTAGTCGCTGAGGTGAGCCT
TGTTTCGGCT 
pOPINF cten1 rev1450 ATGGTCTAGAAAGCTTTAATCTGACGGGGCTCCGG
CGATTATGGA 
pOPINF cten2 for1210 AAGTTCTGTTTCAGGGCCCGGATAAACATCATGTA
CTGAATGTCAAGAGTGGTATATTGCAC 
pOPINF cten2 for1262 AAGTTCTGTTTCAGGGCCCGGGAAATAAGCTTTTG
GCCCCTGTAGCACTG 
pOPINF cten2 rev1607 ATGGTCTAGAAAGCTTTAAGAATTAAGAATGGGCC
TGTTTTTACTGACAGCCCTAATG 
pOPINF cten2 rev1547 ATGGTCTAGAAAGCTTTAGTCTGAAGCTGCCCCTG
CAAGAAGGCATATTT 
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Bioinformatics software (HHpred, I-TASSER, Phyre-2) predicted the different size constructs, 
predicted to contain the beta-propeller, (Table 5.2). 
Table 5.2 Construct boundaries and sizes 
Construct Name (includes boundaries) Length of construct Approximate MW (kDa) 
pOPINF cten1 1112_1510 418 45.4 
pOPINF cten1 1164_1510 366 39.8 
pOPINF cten1 1112_1450 358 39.0 
pOPINF cten1 1164_1450 306 33.5 
pOPINF cten2 1210_1607 417 45.1 
pOPINF cten2 1262_1607 365 39.5 
pOPINF cten2 1210_1547 357 38.7 
pOPINF cten2 1262_1547 305 33.1 
 
Transform the pOPINF vectors containing the different size constructs into TAM1 cells (Active 
Motif) and grow overnight (o/n) at 37°C. Isolate the plasmids with the QIAprep Spin Miniprep 
kit (Qiagen). Vectors can be verified by sequencing with T7 forward and pOPIN reverse primers. 
 Small-scale expression of the constructs was tested in Origami2 DE3 cells (Merck 
Millipore). Origami2 DE3 cells are E. coli K-12 derivatives that enhance disulfide bond 
formation. Note that the recipes of all buffers and media are listed at the end of Materials and 
Methods, in section 5.4. Transform 1 µl of the minipreps into the bacteria on LB-agar plates 
containing 50 µg/ml carbenicillin and 12.5 µg/ml tetracycline. Grow o/n at 37°C and set up 
starter cultures the next day in 96-DWB plates (Abgene). Pick single colonies and inoculate 1.5 
ml GS96 medium (Recipe I), containing glycerol, 1% glucose, 50 µg/ml carbenicillin, and 12.5 
µg/ml tetracycline, and seal the DWB with a gas-permeable adhesive seal (Abgene). Shake the 
plate o/n at 225 rpm and 37°C in a Kühner DWB holder. The next morning, dilute the starter 
culture at 1:50 in 2.5 ml ZYP-5052 autoinduction medium (Recipe II), supplemented with 50 
µg/ml carbenicillin and 12.5 µg/ml tetracycline, in a 24-DWB plate (Abgene). Shake the plate 4-
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5 hours at 225 rpm and 37°C until cultures are cloudy, reduce temperature to 20°C and grow 
another 20 hours. Transfer 1.2 ml of each well into a 96-DWB plate, and spin down for 30 
minutes at 6000 x g and 4°C, using a Beckman Coulter JS5.3 rotor. Carefully remove 
supernatant and freeze pellets on dry ice for at least 30 minutes. Cell pellets can be directly used 
for small-scale purification or stored at -80°C.  
 Re-suspend cell pellets in 280 µl NPI-10-Tween buffer (Recipe III), supplemented with 1 
mg/ml lysozyme and 3 units/ml Benzonase (both Sigma). Shake DWB plate in an orbital shaker 
for 30 minutes at 1400 rpm and 4°C. Spin down for 30 minutes at 6000 x g and 4°C. During the 
centrifugation step, dispense 20 µl of Ni-NTA bead suspension (Qiagen) into a flat-bottom 96-
well plate (MTP, Qiagen). Transfer 180 µl of the cleared lysate into the 96-well plate containing 
the Ni-NTA bead suspension. Mix for 30 minutes at room temperature (RT) and 800 rpm on a 
vortex. Place plate on a 96-well type A magnet (Qiagen) for 2 minutes and carefully remove 
supernatant. To run the different fractions of the small-scale purification on a protein gel, take a 
sample of the supernatant, called flow-through (FT). Add 200 µl NPI-20-Tween wash buffer 
(Recipe IV) to the beads and mix on the vortex shaker for 5 minutes. Place plate on the 96-well 
type A magnet for 2 minutes and carefully remove wash buffer. Repeat wash step once more. 
Take samples of each wash step (W1, W2). Add 25 µl of NPI-250-Tween elution buffer (Recipe 
V) to each of the wells and mix on the vortex shaker for 2 minutes. Place plate on the 96-well 
type A magnet for 2 minutes and transfer the eluate to clean Eppendorf tubes (E). Mix 15 µl of 
the eluate with 5 µl of sample buffer containing DTT, and load 15 µl onto a 17-well NuPAGE 
Novex Bis-Tris protein gel and run for 35 minutes at 200 V in NuPAGE MES SDS running 
buffer, the inner running chamber also containing NuPAGE LDS sample buffer. Take gel out of 
running chamber, remove from the plastic plates it is cast in, and stain in an appropriate plastic 
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dish with enough InstantBlue (Expedeon via Lucerna) to coat the gel. Depending on the amount 
of protein, bands will start to appear in a matter of minutes. Viewing of the bands is improved on 
a bright light source. 
 
5.1.2 Large-scale expression and purification of the cten-2 1262-1607 construct 
 Optimally, pick just one construct that was well-expressed in the small-scale expression 
test (in our case cten-2 1262-1607) and focus on its purification before moving on to the next 
construct. The large-scale expression and purification process requires time, resources and 
enough space, especially in incubators. 
Take a 20 μl aliquot of Origami 2 competent bacteria and leave it on ice for 5 minutes. 
Gently add 1μl of 10 ng/μl pOPINF + cten-2 (1262‐1607) construct to the middle of the bacteria, 
flick the tube once, and incubate for 5min on ice. Heatshock for 30 seconds at 42°C in a 
waterbath. Put back on ice for 2 minutes. Add 80 μl of GS96 + 1% Glucose medium to the 
bacteria and flick gently. Incubate at 37°C for 1 hour without shaking. Carefully spread on a pre‐
warmed/dry LB-Agar plate, supplemented with 12.5 μg/ml Tetracycline and 50 μg/ml 
Carbenicillin. Incubate o/n at 37°C. Keep at 4°C during the day, but inoculate starter culture the 
same day. Inoculate an 80ml starter culture of GS96 + 1% Glucose medium supplemented with 
12.5 μg/ml Tetracycline and 50 μg/ml Carbenicillin with 6 colonies. Incubate overnight at 37°C 
at 225 rpm. Continue with the large‐scale culture the next morning. Add supplements (20x NPS, 
50x 5052, 1M MgSO4) and antibiotics (50 μg/ml Carbenicillin, 12.5 μg/ml Tetracycline) to the 
ZY medium to make a total of 8x 500ml culture (Recipe VI). Dilute 5 ml of overnight starter 
culture (i.e. 1:100) into each of the 2 L flasks, containing the 500 ml medium. Grow for 5 hours 
at 37°C at 225rpm, then turn down the temperature to 20°C for 20 hours. Equally distribute the 4 
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L of culture into 2x 2 L centrifugation containers. Take 1ml sample from each container for a 
small‐scale expression test; i.e. to determine whether the construct was expressed. Harvest cells 
by spinning down both, the 2 L and the 1 ml samples for 30 minutes at 6500 x g and 4°C. 
Remove the medium from the 1 ml samples, directly freeze on dry ice, and store at ‐80°C until 
needed. Also decant medium from the 2 L cultures. Resuspend each cell pellet in 100 ml Lysis 
Buffer (Recipe VII) until it is a homogenous mixture, freeze on dry ice in 50 ml Falcon tubes and 
store at ‐80°C until needed. For the small-scale expression test, quickly thaw the cell pellets at 
RT and follow the protocol of Chapter 5.1.1, starting at re-suspending the cells in NPI-10-Tween 
buffer. If there are few samples (in this case two), the small-scale expression test should be done 
in 1.5 ml Eppendorf tubes, rather than 24- and 96-DWB plates. 
After determining whether the construct is expressed on a small scale, continue with the 
large-scale purification. Slowly thaw re-suspended pellets in beaker filled with water at room 
temperature; exchange water regularly. Meanwhile prepare more lysis buffer, add 4 small tablets 
of protease inhibitor cocktail (Roche) to 20 ml of lysis buffer, and 4 μl of Benzonase (Sigma). 
Incubate lysis buffer on a roller until the tablets have been dissolved. Once the re-suspended 
bacterial pellets are thawed, filter out any debris by pipetting the suspension into a funnel 
containing a piece of cloth, and collecting the flow-through in a clean beaker. Use a cooled down 
EmulsiFlex-C3 cell disruptor (AVESTIN) to lyse the cells. Repeat this step once. Centrifuge the 
lysate in the Beckman Coulter JA‐17 rotor at 30,000 x g for 30 minutes at 4°C. Collect the 
soluble fraction by decanting the supernatant into a clean beaker, keeping it on ice. Filter the 
soluble fraction through a 0.45 μm minisart plus filter (Sartorius Stediim) into 50 ml Falcon 
tubes. Take an aliquot of the soluble cleared lysate (CL) to run as a control on a protein gel. Use 
2 ml of 50% Ni-NTA agarose beads (Qiagen) for 200 ml of cleared lysate, i.e. 1 ml of pure 
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beads. Incubate the cleared lysate – beads mixture on a roller for 1 hour at 4°C. Spin down the 
beads at 500 x g for 5 minutes at 4°C. Carefully transfer the beads with a 5ml pipette into a 25ml 
polyprep column (Bio-Rad). Collect flow‐through (FT), and take an aliquot to run as a control on 
a protein gel. The beads should at least be covered by a minimal amount of liquid at all times. 
Wash the beads twice with 10:1 volumes of Nickel wash buffer (recipe VIII) to Ni-NTA agarose 
beads. Collect each wash step separately (W1, W2) and take an aliquot to run as a control on a 
protein gel. Transfer the washed beads into a 15 ml Falcon tube and fill with Nickel wash buffer 
to 14.5 ml. Add 0.5 ml of 3C protease. The final volume should be close to the maximum 
volume of the tube, so the beads cannot stick to the plastic. Mix well, then incubate o/n at 4°C. 
Keep a small aliquot of the 3C protease (3C) to run as a control on a protein gel. Transfer the 
beads into a 25 ml polyprep column by pouring. Collect the flow-through (3C FT) and take an 
aliquot to run as a control on a protein gel. Pour 5 ml Nickel wash buffer into the Falcon tube to 
wash out the rest of the beads and pour into the column. Take an aliquot from this wash step (3C 
W1), and a second wash step (3C W2), to run both as controls on a protein gel. Elute the 
impurities (3C E) with 10 ml of elution buffer (recipe IX). Mix 15 µl of the samples with 5 µl of 
sample buffer containing DTT, and load 15 µl onto a 12-well NuPAGE Novex Bis-Tris protein 
gel and run for 35 minutes at 200 V in NuPAGE MES SDS running buffer, the inner running 
chamber also containing NuPAGE LDS sample buffer. Take gel out of running chamber, remove 
from the plastic plates it is cast in, and stain in an appropriate plastic dish with enough 
InstantBlue to coat the gel. 
Samples 3C FT, 3C W1, and 3C W2 should contain the protein to be purified. Depending 
on the amount of protein in each sample, combine all, or at least some of the samples for 
continuation of the large-scale purification. Concentrate combined samples using Amicon tubes 
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with 10 kDa cutoff (Merck Millipore), to a volume of less than 2 ml. Load the sample onto an 
Äkta Purifier, using the Hi‐load 16/60 S200 column, for size-exclusion chromatography. Collect 
at least 95 fractions, also containing the protein to be purified. Mix 15 µl of the fractions around 
the predicted protein peak with 5 µl of sample buffer containing DTT, and load 15 µl onto a 12-
well NuPAGE Novex Bis-Tris protein gel and run for 35 minutes at 200 V in NuPAGE MES 
SDS running buffer, the inner running chamber also containing NuPAGE LDS sample buffer. 
Take gel out of running chamber, remove from the plastic plates it is cast in, and stain in an 
appropriate plastic dish with enough InstantBlue to coat the gel. Decide which fractions to pool 
based on the protein, depending on the amount of protein and impurities in the samples. 
Concentrate the combined fractions to a relatively high protein concentration, first using Amicon 
tubes with a 10 kDa cutoff and then a 30 kDa cutoff. Relatively high protein concentration 
means at least 4 mg/ml, but as high as possible before too much of the protein precipitates out of 
solution, depending on the properties of the protein. Protein drops can now be set up in hanging 
drop crystal growth chambers with a Phoenix nano-liter crystallization robot (ARI). Several 
crystallizing conditions, like differing buffers, pH, temperature, or adding proteases can be 
tested. Buffer screens were tested in this study at RT as follows: IndexHT, JBS Solubility, 
JCSGI, JCSGII, JCSGIII, JCSGIV, PEGSI, PEGSII (all Qiagen), MIDAS, Morpheus, PGA (all 
Molecular Dimensions). IndexHT, JCSGI, JCSGII, JCSGIII, JCSGIV screens were also tested at 
RT with trypsin and chymotrypsin, and at 4ºC. 
 
5.1.3 Limited proteolysis 
 Limited proteolysis determines the boundaries of the protein domain to be purified, and 
whether to add any proteases to the crystallization conditions. All limited proteolysis 
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experiments were set up together with the Protein Analysis Facility (PAF) at the FMI, using 
previously purified protein of the cten2 NHL repeat domain (1262-1607). For the general limited 
proteolysis protocol established by the PAF, please refer to Appendix D. Trypsin was used as the 
protease to determine the boundaries. 
 Dissolve enough trypsin powder in 20 mM Tris pH 8.0 + 0.2M NaCl to prepare a 1 
mg/ml stock solution of trypsin. Determine the exact protein concentration by Bradford assay. 
Mix 10 µl of the purified protein solution, optimally containing 10 µg of protein, with differing 
amounts of trypsin in 10 µl of solution (Table 5.3). Incubate 1.5 hours at 37°C and then stop 
reaction with phenylmethanesulfonylfluoride (PMSF). Run samples on a 10% polyacrylamide 
gel, but switch off before dye front has run out of the gel. Stain gel with InstantBlue to view the 
protein fragment bands. 
Table 5.3 Starting concentrations of trypsin in limited proteolysis  
Total amount of trypsin Concentration in 20 µl volume 
0.1 ng 10 µl at 0.01 ng/µl 
0.3 ng 10 µl at 0.03 ng/µl 
1 ng 10 µl at 0.1 ng/µl 
3 ng 10 µl at 0.3 ng/µl 
10 ng 10 µl at 1 ng/µl 
30 ng 10 µl at 3 ng/µl 
100 ng 10 µl at 10 ng/µl 
300 ng 10 µl at 30 ng/µl 
  
Once you have decided, which trypsin concentration gives you several clear and distinct 
fragments, expand on this concentration to optimize this step of the process. Incubation time is 
another variable. Then, up-scale the trypsin concentration to 40-50 µg of purified protein and 
incubate at 37°C for the determined amount time. Stop reaction with PMSF and analyze samples 
by liquid chromatography-mass spectrometry; LTQ Orbitrap Velos (Thermo Scientific) equipped 
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with a Thermo EASY-Spray source or the New Objective Digital Pico View source, coupled to 
an EASY-nLC 1000 Liquid Chromatograph and using Scaffold software (Proteome Software).  
 
5.1.4 Recipes of buffers and media 
 
Recipe I – GS96 medium (per 1 L) 
49.1 g GS96 powder (MP biomedicals) 
0.5 ml glycerol (Sigma) 
Fill up with Milli-Q water, autoclave, and store at 4°C. 
 
Recipe II – ZYP-5052 medium 
ZY medium 463 ml (see recipe VI) 
1 M MgSO4 1 ml 
50 x 5052 10 ml 
20 x NPS 25 ml 
 
1 M MgSO4: 
24.65 g MgSO4-7H2O (Merck) 
Fill up to 500 ml with milli-Q H2O. 
 
50x 5052 (500 ml): 
125 g glycerol (Merck) 
365 ml milli-Q H2O 
12.5 g glucose (Sigma) 
50 g α-lactose (Sigma) 
Fill up to 500 ml with milli-Q H2O. 
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20x NPS: 
450 ml  milli-q H2O 
33 g      (NH4)2SO4 (Merck) 
68 g   KH2PO4 (Merck) 
71 g  Na2HPO4 (Merck) 
Fill up to 500 ml with milli-Q H2O. 
 
Recipe III – NPI-10-Tween buffer 
50 mM NaH2PO4 (Merck) 
300 mM NaCl (Sigma) 
10 mM imidazole (Sigma) 
1% v/v Tween 20 (Sigma) 
Adjust pH to 8.0 using NaOH (Merck); sterile-filter and store at 4°C. 
 
Recipe IV – NPI-20-Tween wash buffer 
50 mM NaH2PO4 (Merck) 
300 mM NaCl (Sigma) 
20 mM imidazole (Sigma) 
0.05% v/v Tween 20 (Sigma) 
Adjust pH to 8.0 using NaOH (Merck); sterile-filter and store at 4°C. 
 
Recipe V – NPI-250-Tween elution buffer 
50 mM NaH2PO4 (Merck) 
300 mM NaCl (Sigma) 
250 mM imidazole (Sigma) 
0.05% v/v Tween 20 (Sigma) 
Adjust pH to 8.0 using NaOH (Merck); sterile-filter and store at 4°C. 
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Recipe VI – ZY medium (per 500 ml) 
5 g tryptone (BD) 
2.5 g yeast extract (BD) 
463 ml milli-Q water 
Autoclave, and store at 4°C. 
 
Recipe VII – Lysis buffer 
50 mM Tris pH 7.5 (VWR) 
500 mM NaCl (Sigma) 
20 mM imidazole (Sigma) 
0.2% Tween (Add 2 ml 10% Tween 20 to 100 ml of Wash buffer) (Sigma) 
0.2 µM sterile-filtered and degassed (just before use). 
 
Recipe VIII – Nickel wash buffer 
50 mM Tris pH 7.5 (VWR) 
500 mM NaCl (Sigma) 
20 mM imidazole (Sigma) 
0.2 µM sterile-filtered and degassed (just before use). 
 
Recipe IX – Elution buffer 
50 mM Tris pH 7.5 (VWR) 
500 mM NaCl (Sigma) 
500 mM imidazole (Sigma) 
0.2 µM sterile-filtered and degassed (just before use). 
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5.2 Results 
 In the recent paper by Beckmann et al., the authors determined through atomic force 
microscopy/single-molecule force spectroscopy experiments which domain is responsible for the 
homophilic rather than heterophilic interaction of the teneurin extracellular domains.88 By 
swapping the different full length chicken teneurin-1 and -2 domains they showed that the NHL 
repeat domain determines the specificity of the homophilic interaction. Interestingly, NHL repeat 
domains are classic beta-propellers, suggesting that a beta-propeller is responsible for 
determining this specificity. Thus, we were interested in purifying the teneurin-1 and -2 NHL 
repeat domains, set up crystallization studies to determine the structure and elucidate the binding 
mechanism of these domains. 
 After insertion into the pOPINF expression vector, the constructs were verified by 
sequencing. There were several point mutations in the constructs, which were already present in 
the original full length chicken teneurin-1 and -2 constructs (Table 5.4). However, these point 
mutations did not appear to be detrimental to the structure or function of the NHL repeat domain 
and were thus not corrected by site-directed mutagenesis. 
Table 5.4 Point mutations identified in chicken teneurin-1 and -2 NHL repeat domain 
constructs 
Teneurin 1 Mutations Teneurin 2 Mutation 
M 1144 V D 1451 N 
P 1419 L  
R 1422 A  
 
Next, we tested the expression of the different constructs on a small scale. Experiments 
were performed in duplicates by auto-induction in Origami2 DE3 cells (Figure 5.1). Since the 
predicted beta-propellers in cten-1 and -2 also contain several disulfide bonds, we chose to work 
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with Origami2 DE3 cells. These particular competent bacteria have a mutation in their 
thioredoxin reductase (trxb) and glutathione reductase (gor) genes, which according to Merck 
Millipore significantly enhances the formation of disulfide bonds. 
 
Figure 5.1 Chicken teneurin-1 and -2 NHL repeat domain constructs 
Small-scale expression test of cten1 and cten2 constructs in duplicates predicted to contain the 
beta-propeller domain. Test expression in Origami2 DE3 cells by auto-induction. Star (*) 
denotes the correct size of the constructs. 
 
Teneurin-2 (1262-1607) was the larger of the two well-expressing constructs and we 
decided to focus on this particular construct first. The other construct, teneurin-2 (1262-1547) is 
missing 60 amino acids at the C-terminal part of the domain, but is identical otherwise. Using the 
larger construct increases the chance that the complete predicted beta-propeller will be 
expressed. Missing part of the domain could be detrimental to the crystallization of the protein, 
since it could be misfolded and unstable. However, the construct should not be too large either. 
Flexible and unfolded domains on either side of the well-structured domain to be crystallized can 
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prevent it from tightly packing in an organized manner. While the predicted beta-propeller would 
be intact, this can also keep the protein from crystallizing. After choosing the cten-2 (1262-1607) 
construct, we up-scaled the expression system to purify larger quantities of the protein. Proteins 
have to be highly concentrated (ideally >4.5 µg/ml) for setting up crystallization studies. We 
performed four purifications of the chosen construct, the results below showing a representative 
round of purification. 
 
Figure 5.2 Retest of chosen construct 
Confirmation of the expression of the cten2 (1262-1607) construct on a small-scale in eight 
randomly picked colonies. 
 
Initially, we retested the expression of the construct on a small-scale before continuing 
with the large-scale culture. All eight randomly picked colonies expressed the construct at about 
39.5 kDa (Figure 5.2). After upscaling the bacterial culture to 4 L, we again tested the expression 
by taking a 1 ml sample from each of the two 2 L cultures, before moving on to the large-scale 
purification (Figure 5.3). To save time in future experiments using this construct, we only test 
expression after up-scaling the bacterial culture. 
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Figure 5.3 Pretesting expression in large-scale culture 
Small-scale expression test of the two 2 L bacterial cultures, before continuing with large-scale 
purification. FT = flow through; W1 = wash 1; W2 = wash 2; E = elution; fractions on the gel are 
explained in more detail in Chapter 5.1. 
 
Once we lysed the cells of the large scale bacterial pellet and removed the insoluble 
fraction and other cell debris, we started with purification by Ni-NTA beads. All constructs in 
the pOPINF vectors are also fused to a His-tag. Thus, we first removed impurities that do not 
bind to the beads by several washing steps. Subsequently we removed impurities that do stick to 
beads, by cleaving the His-tag off the cten-2 construct with 3C-protease and washing it out of the 
column. The protease also contains a His-tag, thus binding to the beads and not contaminating 
the sample. Most of the purified protein is found in the 3C FT and 3C W1 fractions. However, at 
this point the sample contains too many impurities (Figure 5.4). 
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Figure 5.4 Large-scale purification by Ni-NTA agarose beads 
Fractions taken throughout the large-scale purification process, using Ni-NTA agarose beads. 
The cten2 (1262-1607) construct sticks to the beads via its His-tag, which is cleaved off by 3C-
protease, and the construct is subsequently washed out. CL = cleared lysate; FL = flow through; 
W1 = wash 1; W2 = wash 2; 3C = 3C-protease; FT 3C = flow through post-3C cleavage; W1 3C 
= wash 1 post-3C cleavage; W2 3C = wash 2 post-3C cleavage; E 3C = elution post-3C 
cleavage; fractions on the gel are explained in more detail in Chapter 5.2. 
 
 
After concentrating the combined fractions to below 2 ml, we also ran them on a size-exclusion 
chromatography column. Here, we collected a total of 95 fractions, also containing the cten-2 
construct (Figure 5.5). The protein peak around fraction 55 corresponds 39.5 kDa, the calculated 
molecular weight of cten-2 (1262-1607), while the peak around fraction 41 contains an impurity. 
After running the samples on a polyacrylamide gel, we decided to pool fractions 55-64. The ratio 
of purified protein to impurities in the other fractions was too low (Figure 5.6). 
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Figure 5.5 Size-exclusion chromatography 
UV1 spectrum (blue line) shows two distinct protein peaks. Peak 1 around fraction 41 
corresponds to a larger molecular weight than cten2 (1262-1607), while peak 2 around fraction 
55 is approximately the correct size. Fraction numbers are shown in red.  
 
 
Figure 5.6 Fractions including purified protein 
Fifteen fractions collected surrounding the protein peak at fraction 55, including the cten2 (1262-
1607) construct expressed at 39.5 kDa. ‘S200 Load’ is the sample injected into the Äkta purifier. 
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After concentrating the pooled fractions down to 6.5 mg/ml, we set up drops for crystallization in 
chambers containing different crystallization solutions. The following conditions were tested 
thus far: different sets of crystallization solutions, at 4ºC and at RT, and adding the proteases 
trypsin and chymotrypsin. Drops in the different conditions have shown no precipitation, 
complete precipitation, or microspherulite structures (incomplete crystallization), but no crystals 
(Figure 5.7). 
 
Figure 5.7 Crystallization drops 
Examples of the different types of precipitates that appeared in the crystallization drops: A. no 
precipitate B. complete precipitate C. microspherulite structures. 
 
 Limited proteolysis can be utilized to determine the boundaries or stability of a certain 
purified domain. We used it to determine the boundaries of the cten2 (1262-1607) construct, or 
whether there are any unfolded regions on the N- or C-terminal end of the domain. Here, we able 
to show that the construct seems to be stable, with a short seven amino acid C-terminal region 
lysed by trypsin (Figure 5.8). The smaller fragments were all predicted to end within one of the 
beta-propellers, and were thus not potential constructs. Since according to the limited proteolysis 
experiments cten2 (1262-1607) seemed to be almost perfect with only a short C-terminal 
exposed tail, we concluded that our crystallization attempts failed for other reasons than the 
selection of the wrong domain boundaries.  
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 Figure 5.8 Limited Proteolysis 
A. Results from the liquid chromatography-mass spectrometer after limited proteolysis with 
trypsin. Peaks correspond to different size fragments, with molecular weights (Da) and possible 
explanations in parenthesis. Red numbers 1-5 denote the largest fragments, potentially 
containing the full NHL repeat domain. 
B. Red numbers 1-5 show the different fragments from A. in protein gels that ran the limited 
proteolysis samples. 
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6. Conclusion 
Results of my work are discussed in detail in Chapter 4 of the thesis. Here I will include a 
short conclusion for the unpublished results, and discuss how the different studies are related to 
each other. 
Teneurins are an ancient family of proteins with several known functions and features, 
some of which are unique pertaining to eukaryotic proteins. Numerous studies have shown 
teneurins to be involved in the developing CNS, particularly in axon guidance and synapse 
formation. Several ligands for the teneurin ECDs have been described and functions for the ICDs 
include linking teneurins to the cytoskeleton, and influencing transcriptional regulation.84,96 
However, most molecular mechanisms of function have yet to be elucidated. The study presented 
in Chapter 4.1 investigates the evolution of teneurins. Sequence analyses suggest that teneurins 
evolved from Monosiga brevicollis via horizontal gene transfer from an ancient prokaryotic 
protein. YD repeats are one indicator, as they are generally found in bacterial cell wall proteins.82 
In-depth analysis of the structure identifies additional properties and features of teneurins, like 
additional furin cleavage sites where the ECD could be processed, and the probabilities of the 
ICDs to translocate to the nucleus. Due to its importance in teneurin function, there is a focus on 
the ICD. We described splice variants of human and chicken ICDs. Interestingly, no NLS or 
putative binding sites were missing in any of the variants, making a prediction of their functions 
purely speculative. While the full length ICDs have been implicated in influencing 
transcriptional regulation, the splice variants may be involved in other regulatory processes. Our 
study presented in Chapter 4.2 describes a novel mechanism of teneurin ICD function. Here, we 
showed that the TEN1-ICD can influence MITF-dependent transcription of target gene GPNMB, 
by competing for HINT1 binding. In addition to elucidating this molecular mechanism, we also 
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produced a lot of further interesting data when performing the unbiased screens: 1. Yeast-2 
hybrid screen and 2. Whole-transcriptome analyses. The discussion in Chapter 4.2 also contains 
an outlook about determining new functions of the ICDs, especially in the context of our newly 
discovered ICD interacting proteins, as well as genes regulated by the expression of the teneurin-
1 ICD. Examining the splice variants in more detail would be another interesting future direction. 
 The NHL repeat domain is a predicted beta-propeller and is part of all teneurin ECDs. 
While it is not directly involved in transcriptional regulation, it is no less important to the 
function of teneurins. As Beckmann et al. discovered recently, the NHL repeat domain of 
teneurins is responsible for homophilic rather than heterophilic interaction with other teneurins.88 
This interaction likely drives the cleavage of the ECD and subsequently the ICD, which is vital 
for the ICD to affect transcriptional regulation. But how does such a conserved beta-propeller 
distinguish between homophilic over heterophilic interactions? The purification and 
crystallization studies discussed in Chapter 5 were supposed to shed some light into this 
question. While we are able to purify constructs of the NHL repeat domain, they did not 
crystallize in the different conditions we had set up. This is not a trivial process, as several issues 
have to be overcome, such as determining the correct boundaries of the domain, purifying the 
protein with as little impurities as possible at a high concentration yet quick enough for the 
protein not to break down, the domain has to be stable and not flexible, and the purified protein 
has to reproducibly pack into an ordered structure that leads to crystals under certain 
conditions.139 Future studies addressing these issues could finally lead to the crystallization of the 
predicted beta propellers in the teneurin ECDs. We tried to resolve the crystal structure of one 
domain of a larger multi-domain protein. While prediction software was able to estimate 
boundaries for the beta-propeller domain, it is vital for the boundaries to be as close to the 
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domain as possible, while keeping the whole domain intact. Flexible linkers that are not part of 
the folded domain can keep it from tightly packing and thus crystallizing. If the domain is not 
fully intact, it cannot take a stable conformation, and thus will not crystallize either. Since the 
software cannot precisely predict the exact boundaries, it gave us different size constructs that 
are most likely to include the full beta-propeller. Since different protein drop conditions did not 
lead to crystallization of the protein, we tested the boundaries of the protein by limited 
proteolysis, in case there would be unfolded linker regions on either side of the domain. The C-
terminal side did have a short peptide that could be cleaved during limited proteolysis, 
nevertheless proteases did not improve the crystallization process. There are several other 
options that can be tested in future studies. We purified the NHL repeat domain from bacteria. 
While the purification process is quicker and simpler, it may not be optimal for proper folding of 
the domain. Purifying the domain from mammalian cells may be a good option to optimize this 
process. Since the NHL repeat domain is well-conserved between different species and the other 
teneurins, it would be also be a viable option to purify and set up crystallization conditions with 
another teneurin paralog or ortholog. 
Recently, the crystal structure of the BC component of ABC toxins was published.132 
Interestingly, the domain structure is similar to that of the teneurin ECD, particularly the NHL 
repeat domain, YD repeats/RHS protein and the TCAP. Further, the peptide at the very C-
terminal end of the teneurin ECD, TCAP, has a striking sequence similarity to the Tox-GHH 
domain, the toxic peptide of ABC toxins. While the structure of the teneurin ECDs has not been 
solved to date, if modeling the ECD structure after the BC component of ABC toxins, the YD 
repeats would form a barrel, protecting the RHS-protein and Tox-GHH domain (Figure 6.1). 
There are several potential mechanisms of how teneurin ECDs could work in an ABC toxin-like 
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manner. ABC toxins work in two mechanisms of how the toxic peptide gets internalized by the 
target cell, either by forming a pore to inject the peptide or by endocytosis of the entire complex 
and subsequent release inside the cell. Since the ECDs only contain a structural similarity to the 
BC component of ABC toxins, the β-propeller may be responsible for heterophilic binding to a 
protein on another cell, acting as the A protein. Further, homo- or heterophilic interactions could 
lead to the release of the toxic peptide into the extracellular milieu, though this would differ from 
the typical ABC toxin mechanisms. It would be very interesting to study this new aspect of 
teneurin ECDs. A crystal structure of the ECD, at least ranging from the NHL domain to the 
TCAP could prove the structural similarity to ABC toxins. Further, the type of release of the 
teneurin Tox-GHH domain and its function inside the cell or the extracellular milieu could be 
studied. This could be an entirely novel mechanism of action for a eukaryotic protein, and open 
up a new way of thinking about how teneurins function in cell-cell communication. 
 
Figure 6.1 BC component structure132 
Structure of the BC component of the Yersinia entomophaga ABC toxin, with the β-sheets of the 
SpvB, the rest of the B-protein and the CNTR domain forming a central cavity.  
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8. Abbreviations 
• ECM – extracellular matrix 
• CAM – cell adhesion molecule 
• PG – proteoglycan 
• GAG – glycosaminoglycan 
• HA – hyaluronan 
• SLRP – small leucine-rich PGs 
• CNS – central nervous system 
• LM – laminin 
• kDa – kilo-dalton 
• FN – fibronectin 
• p-FN – plasma fibronectin 
• c-FN – cellular fibronectin 
• EGF – epidermal growth factor 
• FA – focal adhesion 
• DDR – discoidin domain receptors 
• Ig – immunoglobulin 
• CDH - cadherin 
• EC – extracellular cadherin 
• ICD – intracellular domain 
• ECD – extracellular domain 
• CR – complement regulatory 
• IgSF – immunoglobulin superfamily 
• N-CAM – neural cell adhesion molecules 
• Nm – nanometer 
• ICM – inner cell mass 
• E13 – embryonic day 13 
• HOX protein – homeobox protein 
• FGF – fibroblast growth factor 
• SHH – sonic hedgehog 
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• WNT – Drosophila wingless 
• BMP – bone morphogenic protein 
• NRG – neuregulin 
• COUP-TFI – chicken ovalbumin upstream promoter transcription factor 1 
• EMX2 – empty spiracles homeobox 2 
• PAX6 – paired box 6 
• SP8 – specificity protein 8 
• F-actin – filamentous actin 
• NTN - netrin 
• DCC – deleted in colorectal carcinoma 
• ROBO - roundabout 
• SEMA - semaphorin 
• PLXN - plexin 
• EFN - ephrin 
• EPH – ephrin receptor 
• NRXN – neurexin 
• NLGN – neuroligin 
• Ten-a – tenascin-like accessory 
• Ten-m – tenascin-like major 
• Odz – odd Oz 
• NLS – nuclear localization signal 
• NHL domain – NCL-1, HT2A and Lin-41 domain 
• SH3 domain – Src-homology 3 domain 
• CRF – corticotrophin releasing factor 
• TCAP – teneurin C-terminal associated peptide 
• RIP – regulated intramembrane proteolysis 
• KO – knockout 
• XLMR – X-linked mental retardation 
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Appendix A - Microarray data of TEN1-ICD overexpression in BS149 cells 
Up-regulated genes (p-value < 0.01; Fold Change > 1.5) 
Gene Name Gene Description Fold Change 
A2M alpha-2-macroglobulin 1.69 
ABI3BP ABI family, member 3 (NESH) binding protein 1.56 
ACAT2 acetyl-CoA acetyltransferase 2 1.50 
ACSS2 acyl-CoA synthetase short-chain family member 2 1.59 
ADAM22 ADAM metallopeptidase domain 22 1.54 
AFAP1L2 actin filament associated protein 1-like 2 1.77 
AGPHD1 aminoglycoside phosphotransferase domain containing 1 1.57 
AIF1L allograft inflammatory factor 1-like 1.52 
ALDOC aldolase C, fructose-bisphosphate 2.35 
ALX1 ALX homeobox 1 3.29 
ANGPTL1 angiopoietin-like 1 1.58 
ANKRD30A ankyrin repeat domain 30A 2.05 
APOD apolipoprotein D 1.65 
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 1.62 
ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 1.93 
AZGP1 alpha-2-glycoprotein 1, zinc-binding 2.42 
B3GALT1 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 1.82 
BGN biglycan 3.34 
BST2 bone marrow stromal cell antigen 2 1.56 
BTG2 BTG family, member 2 1.55 
C1R complement component 1, r subcomponent 1.65 
C3 complement component 3 3.69 
C5orf4 chromosome 5 open reading frame 4 2.12 
C6orf192 chromosome 6 open reading frame 192 1.95 
C7orf58 chromosome 7 open reading frame 58 1.75 
CA12 carbonic anhydrase XII 1.95 
CA9 carbonic anhydrase IX 1.78 
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 2.18 
CADM3 cell adhesion molecule 3 1.63 
CCL20 chemokine (C-C motif) ligand 20 1.56 
CCL5 chemokine (C-C motif) ligand 5 2.93 
CDH19 cadherin 19, type 2 1.66 
CELF2 CUGBP, Elav-like family member 2 1.58 
CFI complement factor I 1.59 
CHL1 cell adhesion molecule with homology to L1CAM (close homolog of L1) 3.43 
CHRDL1 chordin-like 1 2.99 
CHRNA6 cholinergic receptor, nicotinic, alpha 6 2.69 
CKB creatine kinase, brain 1.69 
CMTM5 CKLF-like MARVEL transmembrane domain containing 5 1.90 
CNTN1 contactin 1 2.20 
CP ceruloplasmin (ferroxidase) 1.56 
CPE carboxypeptidase E 1.63 
CRELD1 cysteine-rich with EGF-like domains 1 1.57 
CSGALNACT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 1.72 
CXADR coxsackie virus and adenovirus receptor 2.42 
DAAM2 dishevelled associated activator of morphogenesis 2 1.55 
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 1.59 
DEPDC6 DEP domain containing 6 1.91 
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DEPDC7 DEP domain containing 7 1.90 
DHCR7 7-dehydrocholesterol reductase 2.22 
DKFZp434F142 hypothetical DKFZp434F142 1.52 
DOCK4 dedicator of cytokinesis 4 1.83 
EDIL3 EGF-like repeats and discoidin I-like domains 3 1.52 
EDNRB endothelin receptor type B 2.14 
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 1.72 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 2.35 
EXTL1 exostoses (multiple)-like 1 1.84 
FABP7 fatty acid binding protein 7, brain 1.91 
FADS2 fatty acid desaturase 2 2.79 
FAIM2 Fas apoptotic inhibitory molecule 2 1.61 
FAM134B family with sequence similarity 134, member B 3.06 
FAM198B family with sequence similarity 198, member B 1.60 
FAM70A family with sequence similarity 70, member A 2.10 
FAM99A family with sequence similarity 99, member A 1.56 
FCRLA Fc receptor-like A 3.61 
FDFT1 farnesyl-diphosphate farnesyltransferase 1 1.54 
FHL1 four and a half LIM domains 1 2.15 
FLJ35776 hypothetical LOC649446 1.56 
FOXP2 forkhead box P2 1.77 
FXYD3 FXYD domain containing ion transport regulator 3 3.21 
GAS7 growth arrest-specific 7 1.71 
GBP2 guanylate binding protein 2, interferon-inducible 1.56 
GLB1L galactosidase, beta 1-like 1.60 
GMFG glia maturation factor, gamma 1.59 
GPCPD1 glycerophosphocholine phosphodiesterase GDE1 homolog (S. cerevisiae) 1.71 
GPNMB glycoprotein (transmembrane) nmb 2.41 
GPR155 G protein-coupled receptor 155 1.79 
GPR162 G protein-coupled receptor 162 1.68 
GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) 2.13 
GRAMD3 GRAM domain containing 3 1.64 
GSTA4 glutathione S-transferase alpha 4 1.55 
HCG27 HLA complex group 27 1.76 
HEXIM1 hexamethylene bis-acetamide inducible 1 1.54 
HEY2 hairy/enhancer-of-split related with YRPW motif 2 2.39 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 4.80 
HMCN1 hemicentin 1 2.16 
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 2.00 
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 2.11 
HOXA5 homeobox A5 1.94 
HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7 2.07 
HSD17B7P2 hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2 1.72 
ID4 inhibitor of DNA binding 4, dominant negative helix-loop-helix protein 1.53 
IDI1 isopentenyl-diphosphate delta isomerase 1 1.86 
IFI35 interferon-induced protein 35 1.53 
IFIH1 interferon induced with helicase C domain 1 1.62 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 1.80 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 1.85 
IFITM1 interferon induced transmembrane protein 1 (9-27) 2.78 
IFITM2 interferon induced transmembrane protein 2 (1-8D) 1.94 
IGFBP5 insulin-like growth factor binding protein 5 1.88 
IGLJ3 immunoglobulin lambda joining 3 1.92 
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INSIG1 insulin induced gene 1 2.96 
ITGA9 integrin, alpha 9 1.60 
ITIH5L inter-alpha (globulin) inhibitor H5-like 2.08 
ITPR2 inositol 1,4,5-triphosphate receptor, type 2 1.63 
KCND1 potassium voltage-gated channel, Shal-related subfamily, member 1 1.53 
KCNK5 potassium channel, subfamily K, member 5 1.62 
KIAA1161 KIAA1161 1.59 
KLF9 Kruppel-like factor 9 2.00 
KLHL13 kelch-like 13 (Drosophila) 1.53 
KLHL24 kelch-like 24 (Drosophila) 1.60 
LAMA4 laminin, alpha 4 2.45 
LAPTM5 lysosomal protein transmembrane 5 1.50 
LASS4 LAG1 homolog, ceramide synthase 4 1.60 
LDLR low density lipoprotein receptor 1.57 
LGMN legumain 1.53 
LIFR leukemia inhibitory factor receptor alpha 1.54 
LIPG lipase, endothelial 1.56 
LOC400804 hypothetical LOC400804 1.59 
LRRTM4 leucine rich repeat transmembrane neuronal 4 1.73 
LSAMP limbic system-associated membrane protein 1.93 
LUZP4 leucine zipper protein 4 1.92 
LY96 lymphocyte antigen 96 1.60 
MANSC1 MANSC domain containing 1 1.55 
MAOB monoamine oxidase B 1.70 
MAP3K12 mitogen-activated protein kinase kinase kinase 12 1.53 
METTL7A methyltransferase like 7A 1.55 
MGP matrix Gla protein 1.90 
MIR186 microRNA 186 1.51 
MKNK2 MAP kinase interacting serine/threonine kinase 2 1.51 
MMP16 matrix metallopeptidase 16 (membrane-inserted) 1.64 
MMP16 matrix metallopeptidase 16 (membrane-inserted) 1.50 
MMP19 matrix metallopeptidase 19 1.82 
MRGPRX4 MAS-related GPR, member X4 1.76 
MYEF2 myelin expression factor 2 1.54 
NCALD neurocalcin delta 2.03 
NCAM2 neural cell adhesion molecule 2 1.75 
NFIA nuclear factor I/A 2.63 
NR4A1 nuclear receptor subfamily 4, group A, member 1 2.26 
NR4A2 nuclear receptor subfamily 4, group A, member 2 2.45 
NRCAM neuronal cell adhesion molecule 2.65 
OASL 2'-5'-oligoadenylate synthetase-like 1.55 
ODZ1 odz, odd Oz/ten-m homolog 1(Drosophila) 2.79 
ORAI3 ORAI calcium release-activated calcium modulator 3 1.64 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.76 
PCDH10 protocadherin 10 2.13 
PDE3A phosphodiesterase 3A, cGMP-inhibited 2.23 
PDE4B phosphodiesterase 4B, cAMP-specific (E4 dunce homolog, Drosophila) 1.68 
PDE7B phosphodiesterase 7B 1.72 
PDGFRL platelet-derived growth factor receptor-like 1.56 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 1.59 
PELI1 pellino homolog 1 (Drosophila) 1.54 
PHLPP1 PH domain and leucine rich repeat protein phosphatase 1 1.51 
PLAC1 placenta-specific 1 1.57 
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PLCD4 phospholipase C, delta 4 1.66 
PLD1 phospholipase D1, phosphatidylcholine-specific 1.52 
PLEKHH1 pleckstrin homology domain containing, family H (with MyTH4 domain) 1 1.53 
PLP1 proteolipid protein 1 1.87 
PMP2 peripheral myelin protein 2 2.58 
PNPLA3 patatin-like phospholipase domain containing 3 2.40 
PODXL podocalyxin-like 1.69 
PRELP proline/arginine-rich end leucine-rich repeat protein 3.41 
PTGS1 prostaglandin-endoperoxide synthase 1 1.93 
PTPN13 protein tyrosine phosphatase, non-receptor type 13 1.63 
PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 2.54 
PTTG1 pituitary tumor-transforming 1 1.50 
RAB3A RAB3A, member RAS oncogene family 1.69 
RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 1.78 
RASSF4 Ras association (RalGDS/AF-6) domain family member 4 1.62 
RDH11 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 1.52 
RFTN2 raftlin family member 2 1.97 
RNF150 ring finger protein 150 1.84 
ROBO1 roundabout, axon guidance receptor, homolog 1 (Drosophila) 1.55 
ROBO2 roundabout, axon guidance receptor, homolog 2 (Drosophila) 1.96 
RPE65 retinal pigment epithelium-specific protein 65kDa 1.90 
RXRG retinoid X receptor, gamma 2.59 
S100A3 S100 calcium binding protein A3 1.72 
S100B S100 calcium binding protein B 1.79 
SAA1 serum amyloid A1 4.48 
SAT1 spermidine/spermine N1-acetyltransferase 1 1.93 
SC4MOL sterol-C4-methyl oxidase-like 1.83 
SCARB1 scavenger receptor class B, member 1 2.02 
SCD stearoyl-CoA desaturase (delta-9-desaturase) 2.44 
SCRG1 stimulator of chondrogenesis 1 2.92 
SDF2L1 stromal cell-derived factor 2-like 1 1.68 
SEMA3A semaphorin 3A 1.55 
SEMA3D semaphorin 3D 1.59 
SEMA4B semaphorin 4B 1.68 
SEMA4G semaphorin 4G 1.61 
SEMA6A semaphorin 6A 1.55 
SEPT4 septin 4 1.76 
SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 5 1.63 
SKAP2 src kinase associated phosphoprotein 2 1.78 
SLAIN1 SLAIN motif family, member 1 2.10 
SLC16A4 solute carrier family 16, member 4 (monocarboxylic acid transporter 5) 1.58 
SLC1A1 solute carrier family 1 (neuronal/epithelial glutamate transporter) 1 1.53 
SLC1A4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 1.57 
SLC25A45 solute carrier family 25, member 45 1.67 
SLC29A2 solute carrier family 29 (nucleoside transporters), member 2 1.51 
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 1.57 
SLC35F1 solute carrier family 35, member F1 1.59 
SLC38A3 solute carrier family 38, member 3 1.81 
SLC44A2 solute carrier family 44, member 2 1.53 
SLCO4A1 solute carrier organic anion transporter family, member 4A1 1.85 
SOBP sine oculis binding protein homolog (Drosophila) 1.66 
SOD2 superoxide dismutase 2, mitochondrial 2.08 
SOD3 superoxide dismutase 3, extracellular 1.74 
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SOX5 SRY (sex determining region Y)-box 5 1.89 
SPRY1 sprouty homolog 1, antagonist of FGF signaling (Drosophila) 1.50 
SQLE squalene epoxidase 1.93 
SREBF1 sterol regulatory element binding transcription factor 1 1.69 
SREBF2 sterol regulatory element binding transcription factor 2 2.00 
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 1.54 
ST8SIA1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 2.28 
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 1.89 
STARD4 StAR-related lipid transfer (START) domain containing 4 2.66 
STC1 stanniocalcin 1 1.65 
STMN2 stathmin-like 2 1.57 
TDRKH tudor and KH domain containing 1.74 
TF transferrin 1.64 
TGFBR3 transforming growth factor, beta receptor III 1.54 
THBS2 thrombospondin 2 1.71 
THBS3 thrombospondin 3 1.52 
TMEM135 transmembrane protein 135 1.51 
TMEM195 transmembrane protein 195 1.65 
TMEM229B transmembrane protein 229B 2.53 
TMPRSS15 transmembrane protease, serine 15 1.51 
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 2.26 
TNFRSF19 tumor necrosis factor receptor superfamily, member 19 2.58 
TP53INP1 tumor protein p53 inducible nuclear protein 1 1.59 
TPCN1 two pore segment channel 1 1.50 
TRIM9 tripartite motif-containing 9 1.58 
TRPM8 transient receptor potential cation channel, subfamily M, member 8 2.26 
TTC28 tetratricopeptide repeat domain 28 1.77 
TUBB4 tubulin, beta 4 2.13 
USP2 ubiquitin specific peptidase 2 1.88 
WIPI1 WD repeat domain, phosphoinositide interacting 1 1.57 
YPEL2 yippee-like 2 (Drosophila) 1.66 
ZKSCAN1 zinc finger with KRAB and SCAN domains 1 1.51 
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Down-regulated genes (p-value < 0.01; Fold Change < -1.5) 
Gene Name Gene Description Fold Change 
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 -1.66 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 -1.62 
ABLIM3 actin binding LIM protein family, member 3 -1.71 
ACPL2 acid phosphatase-like 2 -1.56 
ACTBL2 actin, beta-like 2 -2.31 
ADD2 adducin 2 (beta) -2.10 
ADRA1B adrenergic, alpha-1B-, receptor -2.23 
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 -1.55 
AK3L1 adenylate kinase 3-like 1 -1.56 
AKR1C2 aldo-keto reductase family 1, member C2 -2.64 
AKR1C3 aldo-keto reductase family 1, member C3 -1.93 
ALDH1A3 aldehyde dehydrogenase 1 family, member A3 -1.84 
AMIGO2 adhesion molecule with Ig-like domain 2 -3.65 
ANGPTL4 angiopoietin-like 4 -3.90 
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) -6.63 
ANO1 anoctamin 1, calcium activated chloride channel -1.93 
AOC2 amine oxidase, copper containing 2 (retina-specific) -1.56 
APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G -1.51 
ARRDC3 arrestin domain containing 3 -1.52 
AVEN apoptosis, caspase activation inhibitor -1.51 
B3GALNT1 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) -1.91 
BCAR3 breast cancer anti-estrogen resistance 3 -1.65 
BCL2L1 BCL2-like 1 -1.51 
BDNF brain-derived neurotrophic factor -1.62 
BEND6 BEN domain containing 6 -1.66 
BHLHE41 basic helix-loop-helix family, member e41 -1.81 
BLID BH3-like motif containing, cell death inducer -1.50 
C3orf59 chromosome 3 open reading frame 59 -1.66 
C6orf138 chromosome 6 open reading frame 138 -1.81 
C6orf145 chromosome 6 open reading frame 145 -1.64 
C6orf168 chromosome 6 open reading frame 168 -1.57 
C6orf191 chromosome 6 open reading frame 191 -1.56 
CA8 carbonic anhydrase VIII -1.92 
CALB2 calbindin 2 -2.35 
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 -2.03 
CAV2 caveolin 2 -1.63 
CCND1 cyclin D1 -1.67 
CCNE2 cyclin E2 -1.67 
CDC25A cell division cycle 25 homolog A (S. pombe) -1.56 
CDRT1 CMT1A duplicated region transcript 1 -2.40 
CDRT1 CMT1A duplicated region transcript 1 -2.26 
CDRT1 CMT1A duplicated region transcript 1 -2.15 
CNGA2 cyclic nucleotide gated channel alpha 2 -2.46 
CPA4 carboxypeptidase A4 -1.61 
CPEB1 cytoplasmic polyadenylation element binding protein 1 -1.50 
CYTSB cytospin B -1.51 
DCBLD1 discoidin, CUB and LCCL domain containing 1 -1.82 
DCLK2 doublecortin-like kinase 2 -1.55 
DDAH1 dimethylarginine dimethylaminohydrolase 1 -1.81 
DKK1 dickkopf homolog 1 (Xenopus laevis) -2.83 
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DLX2 distal-less homeobox 2 -1.75 
DPYSL3 dihydropyrimidinase-like 3 -1.57 
DUSP10 dual specificity phosphatase 10 -1.67 
EDA2R ectodysplasin A2 receptor -1.69 
EDN1 endothelin 1 -1.62 
EFNB2 ephrin-B2 -1.99 
EGFR epidermal growth factor receptor -1.72 
EGR2 early growth response 2 -1.90 
EID3 EP300 interacting inhibitor of differentiation 3 -1.59 
EIF4E3 eukaryotic translation initiation factor 4E family member 3 -1.68 
EMB embigin homolog (mouse) -1.76 
EPB41L4A erythrocyte membrane protein band 4.1 like 4A -2.43 
EPHA2 EPH receptor A2 -1.54 
EPHB2 EPH receptor B2 -2.11 
ERRFI1 ERBB receptor feedback inhibitor 1 -1.63 
ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) -1.93 
F3 coagulation factor III (thromboplastin, tissue factor) -1.57 
FAM105A family with sequence similarity 105, member A -1.81 
FAM171A1 family with sequence similarity 171, member A1 -1.82 
FAT4 FAT tumor suppressor homolog 4 (Drosophila) -1.62 
FERMT1 fermitin family homolog 1 (Drosophila) -1.54 
FGF12 fibroblast growth factor 12 -1.61 
FJX1 four jointed box 1 (Drosophila) -1.65 
GADD45A growth arrest and DNA-damage-inducible, alpha -1.71 
GAP43 growth associated protein 43 -1.57 
GCLC glutamate-cysteine ligase, catalytic subunit -1.71 
GCLM glutamate-cysteine ligase, modifier subunit -1.52 
GDF15 growth differentiation factor 15 -2.06 
GFPT2 glutamine-fructose-6-phosphate transaminase 2 -1.67 
GHR growth hormone receptor -1.69 
GRAMD1C GRAM domain containing 1C -1.68 
GTF2IRD2B GTF2I repeat domain containing 2B -2.42 
HEG1 HEG homolog 1 (zebrafish) -1.66 
HERC3 hect domain and RLD 3 -2.13 
HMGA2 high mobility group AT-hook 2 -1.61 
HOXC11 homeobox C11 -1.54 
HOXC13 homeobox C13 -1.71 
ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein -1.76 
IL7R interleukin 7 receptor -2.39 
INHBA inhibin, beta A -1.70 
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) -1.63 
JAG1 jagged 1 (Alagille syndrome) -1.64 
JUB jub, ajuba homolog (Xenopus laevis) -1.59 
KCNH1 potassium voltage-gated channel, subfamily H (eag-related), member 1 -2.05 
KIAA0748 KIAA0748 -1.58 
KIAA1644 KIAA1644 -1.68 
KLHL21 kelch-like 21 (Drosophila) -1.54 
KLHL4 kelch-like 4 (Drosophila) -2.26 
KLK6 kallikrein-related peptidase 6 -1.58 
KLKB1 kallikrein B, plasma (Fletcher factor) 1 -1.53 
KRT81 keratin 81 -1.61 
LIF leukemia inhibitory factor (cholinergic differentiation factor) -1.51 
LIMCH1 LIM and calponin homology domains 1 -1.70 
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LOC100133299 GALI1870 -1.51 
LOC151009 hypothetical LOC151009 -1.52 
LOC402778 CD225 family protein FLJ76511 -3.65 
LPHN3 latrophilin 3 -2.27 
LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 -1.76 
LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 -1.61 
LTBP1 latent transforming growth factor beta binding protein 1 -1.70 
LYPD6 LY6/PLAUR domain containing 6 -1.60 
MAGEC2 melanoma antigen family C, 2 -1.53 
MAP1B microtubule-associated protein 1B -1.58 
MGLL monoglyceride lipase -1.84 
MICAL2 microtubule associated monoxygenase, calponin and LIM domain cont. 2 -1.95 
MIR221 microRNA 221 -1.75 
MLPH melanophilin -2.11 
MT1E metallothionein 1E -1.62 
MT1F metallothionein 1F -1.90 
MTTP microsomal triglyceride transfer protein -1.56 
MYC v-myc myelocytomatosis viral oncogene homolog (avian) -2.14 
MYPN myopalladin -3.31 
NAV3 neuron navigator 3 -2.02 
NEO1 neogenin homolog 1 (chicken) -2.46 
NEXN nexilin (F actin binding protein) -2.25 
NGFR nerve growth factor receptor -2.37 
NIPSNAP3A nipsnap homolog 3A (C. elegans) -1.55 
NPIPL3 nuclear pore complex interacting protein-like 3 -1.86 
NPTX2 neuronal pentraxin II -1.74 
NRG1 neuregulin 1 -2.49 
NRP1 neuropilin 1 -1.70 
OBFC2A oligonucleotide/oligosaccharide-binding fold containing 2A -1.52 
ODZ2 odz, odd Oz/ten-m homolog 2 (Drosophila) -1.54 
PAQR5 progestin and adipoQ receptor family member V -1.53 
PAWR PRKC, apoptosis, WT1, regulator -1.75 
PCBP3 poly(rC) binding protein 3 -1.70 
PDE1C phosphodiesterase 1C, calmodulin-dependent 70kDa -2.05 
PER2 period homolog 2 (Drosophila) -1.53 
PGM5P2 phosphoglucomutase 5 pseudogene 2 -1.60 
PHF15 PHD finger protein 15 -1.55 
PHLDB2 pleckstrin homology-like domain, family B, member 2 -1.58 
PLXNA1 plexin A1 -1.61 
PLXNA2 plexin A2 -1.80 
PORCN porcupine homolog (Drosophila) -1.79 
PRKAG2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit -1.64 
PRR16 proline rich 16 -1.57 
PRR4 proline rich 4 (lacrimal) -1.71 
PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa -2.20 
PTHLH parathyroid hormone-like hormone -2.79 
PTPN22 protein tyrosine phosphatase, non-receptor type 22 (lymphoid) -2.05 
PTPRB protein tyrosine phosphatase, receptor type, B -1.56 
PTX3 pentraxin 3, long -1.73 
QRFPR pyroglutamylated RFamide peptide receptor -1.92 
RAB27B RAB27B, member RAS oncogene family -1.74 
RAC2 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP BP Rac2) -1.67 
RAD51 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) -1.56 
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RALGPS2 Ral GEF with PH domain and SH3 binding motif 2 -1.79 
RBPMS RNA binding protein with multiple splicing -1.61 
RGAG1 retrotransposon gag domain containing 1 -1.66 
RGNEF 190 kDa guanine nucleotide exchange factor -1.64 
RGS20 regulator of G-protein signaling 20 -1.52 
RGS7 regulator of G-protein signaling 7 -1.86 
RNU5D RNA, U5D small nuclear -1.66 
RPSAP52 ribosomal protein SA pseudogene 52 -3.26 
SCG2 secretogranin II -1.54 
SCNN1A sodium channel, nonvoltage-gated 1 alpha -1.67 
SDC1 syndecan 1 -1.77 
SEMA4A Semaphoring 4A -1.84 
SERINC5 serine incorporator 5 -2.18 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 -1.92 
SERPINB5 serpin peptidase inhibitor, clade B (ovalbumin), member 5 -1.53 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, PAI type 1), member 1 -3.38 
SH3RF2 SH3 domain containing ring finger 2 -2.20 
SLC12A8 solute carrier family 12 (potassium/chloride transporters), member 8 -1.69 
SLC16A6 solute carrier family 16, member 6 (monocarboxylic acid transporter 7) -3.38 
SLC35F2 solute carrier family 35, member F2 -1.61 
SLC37A1 solute carrier family 37 (glycerol-3-phosphate transporter) 1 -1.63 
SLC37A2 solute carrier family 37 (glycerol-3-phosphate transporter) 2 -1.65 
SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) 11 -2.75 
SMAD7 SMAD family member 7 -1.82 
SMAGP small cell adhesion glycoprotein -1.68 
SNAI2 snail homolog 2 (Drosophila) -2.02 
SPAG11B sperm associated antigen 11B -1.69 
SPANXA2 SPANX family, member A2 -1.60 
SPANXE SPANX family, member E -1.84 
SPRR2D small proline-rich protein 2D -1.62 
SRXN1 sulfiredoxin 1 homolog (S. cerevisiae) -1.71 
SSX4 synovial sarcoma, X breakpoint 4 -1.62 
SSX6 synovial sarcoma, X breakpoint 6 (pseudogene) -1.51 
STAC SH3 and cysteine rich domain -1.78 
STC2 stanniocalcin 2 -2.40 
STRA6 stimulated by retinoic acid gene 6 homolog (mouse) -1.51 
STX1A syntaxin 1A (brain) -1.53 
SULT1B1 sulfotransferase family, cytosolic, 1B, member 1 -1.56 
SYNC syncoilin, intermediate filament protein -1.59 
TBX3 T-box 3 -1.88 
TBXAS1 thromboxane A synthase 1 (platelet) -1.69 
TCF19 transcription factor 19 -1.70 
TGFB2 transforming growth factor, beta 2 -2.03 
TGFBR2 transforming growth factor, beta receptor II (70/80kDa) -1.50 
TGM2 transglutaminase 2 -1.52 
THSD4 thrombospondin, type I, domain containing 4 -1.86 
TINAGL1 tubulointerstitial nephritis antigen-like 1 -1.76 
TLR4 toll-like receptor 4 -1.83 
TM4SF18 transmembrane 4 L six family member 18 -1.96 
TMEM171 transmembrane protein 171 -1.77 
TMEM183A transmembrane protein 183A -1.80 
TMTC1 transmembrane and tetratricopeptide repeat containing 1 -1.51 
TRHDE thyrotropin-releasing hormone degrading enzyme -3.16 
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TRIM16L tripartite motif-containing 16-like -1.75 
TRIM22 tripartite motif-containing 22 -1.66 
TRIM73 tripartite motif-containing 73 -1.86 
TRIML2 tripartite motif family-like 2 -2.02 
TRPA1 transient receptor potential cation channel, subfamily A, member 1 -2.10 
TRPC1 transient receptor potential cation channel, subfamily C, member 1 -1.53 
TSKU tsukushi small leucine rich proteoglycan homolog (Xenopus laevis) -1.51 
TXNRD1 thioredoxin reductase 1 -1.94 
UNG uracil-DNA glycosylase -1.55 
VLDLR very low density lipoprotein receptor -1.68 
WNT5A wingless-type MMTV integration site family, member 5A -1.90 
XAGE1A X antigen family, member 1A -1.58 
ZNF365 zinc finger protein 365 -1.51 
ZNF643 zinc finger protein 643 -1.56 
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Appendix B - Microarray data of MITF overexpression in BS149 cells 
Up-regulated genes (p-value < 0.01; Fold Change > 1.5) 
Gene Name Gene Description Fold Change 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 1.79 
ABHD6 abhydrolase domain containing 6 1.96 
ACTN2 actinin, alpha 2 3.54 
ADM adrenomedullin 2.00 
AGXT2L2 alanine-glyoxylate aminotransferase 2-like 2 1.51 
AHNAK2 AHNAK nucleoprotein 2 3.93 
AIFM1 apoptosis-inducing factor, mitochondrion-associated, 1 1.90 
ALDH1L2 aldehyde dehydrogenase 1 family, member L2 1.56 
ALOXE3 arachidonate lipoxygenase 3 1.67 
ALS2CR12 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 12 2.55 
ALS2CR8 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8 1.55 
AMDHD2 amidohydrolase domain containing 2 2.07 
AMZ2P1 archaelysin family metallopeptidase 2 pseudogene 1 1.97 
ANGPTL2 angiopoietin-like 2 3.59 
ANKMY2 ankyrin repeat and MYND domain containing 2 1.73 
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 3.41 
AP1AR adaptor-related protein complex 1 associated regulatory protein 1.57 
APBB3 amyloid beta (A4) precursor protein-binding, family B, member 3 1.64 
ARFGAP1 ADP-ribosylation factor GTPase activating protein 1 1.67 
ARMCX1 armadillo repeat containing, X-linked 1 1.66 
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 2.37 
ATG2B ATG2 autophagy related 2 homolog B (S. cerevisiae) 1.61 
ATP6V0D1 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 1.57 
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 10.18 
ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 1.71 
ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 1.76 
ATP6V1F ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F 1.71 
ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H 1.72 
ATP7A ATPase, Cu++ transporting, alpha polypeptide 2.45 
ATXN7L1 ataxin 7-like 1 1.56 
BAIAP2 BAI1-associated protein 2 1.96 
BBS7 Bardet-Biedl syndrome 7 1.83 
BEST1 bestrophin 1 6.95 
BHLHE41 basic helix-loop-helix family, member e41 2.07 
BLVRB biliverdin reductase B (flavin reductase (NADPH)) 1.64 
BNC2 basonuclin 2 2.11 
C12orf49 chromosome 12 open reading frame 49 2.80 
C12orf50 chromosome 12 open reading frame 50 1.86 
C12orf66 chromosome 12 open reading frame 66 1.72 
C14orf128 chromosome 14 open reading frame 128 1.63 
C14orf129 chromosome 14 open reading frame 129 1.55 
C14orf79 chromosome 14 open reading frame 79 1.80 
C15orf34 chromosome 15 open reading frame 34 2.48 
C18orf19 chromosome 18 open reading frame 19 1.85 
C1orf189 chromosome 1 open reading frame 189 1.78 
C1orf51 chromosome 1 open reading frame 51 1.53 
C1orf85 chromosome 1 open reading frame 85 1.57 
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C1orf97 chromosome 1 open reading frame 97 1.51 
C20orf165 chromosome 20 open reading frame 165 1.53 
C21orf90 chromosome 21 open reading frame 90 2.17 
C21orf91 chromosome 21 open reading frame 91 1.74 
C22orf25 chromosome 22 open reading frame 25 3.08 
C2orf86 chromosome 2 open reading frame 86 1.54 
C6orf115 chromosome 6 open reading frame 115 1.54 
C6orf192 chromosome 6 open reading frame 192 1.66 
C9orf91 chromosome 9 open reading frame 91 1.90 
CAB39L calcium binding protein 39-like 1.51 
CABLES1 Cdk5 and Abl enzyme substrate 1 3.67 
CAMKK1 calcium/calmodulin-dependent protein kinase kinase 1, alpha 1.72 
CCBE1 collagen and calcium binding EGF domains 1 1.71 
CCDC110 coiled-coil domain containing 110 1.68 
CCDC113 coiled-coil domain containing 113 1.58 
CCDC43 coiled-coil domain containing 43 1.63 
CDK20 cyclin-dependent kinase 20 1.81 
CDSN corneodesmosin 11.45 
CEP250 centrosomal protein 250kDa 1.76 
CGB2 chorionic gonadotropin, beta polypeptide 2 1.58 
CHKA choline kinase alpha 2.00 
CHRM4 cholinergic receptor, muscarinic 4 1.79 
CHRNB2 cholinergic receptor, nicotinic, beta 2 (neuronal) 2.04 
CLCN6 chloride channel 6 2.28 
CLCN7 chloride channel 7 2.23 
CLDN12 claudin 12 1.62 
CLN3 ceroid-lipofuscinosis, neuronal 3 1.68 
CLN6 ceroid-lipofuscinosis, neuronal 6, late infantile, variant 1.54 
COPZ2 coatomer protein complex, subunit zeta 2 1.51 
CPNE7 copine VII 1.85 
CPSF4 cleavage and polyadenylation specific factor 4, 30kDa 2.01 
CRY1 cryptochrome 1 (photolyase-like) 1.96 
CTNS cystinosis, nephropathic 2.49 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 2.09 
CYP2U1 cytochrome P450, family 2, subfamily U, polypeptide 1 2.23 
DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 1.71 
DCT dopachrome tautomerase 1.58 
DDI2 DNA-damage inducible 1 homolog 2 (S. cerevisiae) 1.58 
DDIT3 DNA-damage-inducible transcript 3 2.15 
DET1 de-etiolated homolog 1 (Arabidopsis) 1.51 
DEXI Dexi homolog (mouse) 4.40 
DFNB31 deafness, autosomal recessive 31 1.82 
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 1.59 
DNAL4 dynein, axonemal, light chain 4 1.53 
DNER delta/notch-like EGF repeat containing 2.20 
DOCK10 dedicator of cytokinesis 10 1.56 
DPP4 dipeptidyl-peptidase 4 2.27 
DPY19L2 dpy-19-like 2 (C. elegans) 1.62 
DPY19L2P1 dpy-19-like 2 pseudogene 1 (C. elegans) 1.68 
DPY19L2P2 dpy-19-like 2 pseudogene 2 (C. elegans) 1.73 
DUSP10 dual specificity phosphatase 10 1.95 
DUSP3 dual specificity phosphatase 3 1.54 
DYRK3 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 3.08 
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EEA1 early endosome antigen 1 1.61 
EEF1A2 eukaryotic translation elongation factor 1 alpha 2 1.55 
EEPD1 endonuclease/exonuclease/phosphatase family domain containing 1 1.82 
EFTUD1 elongation factor Tu GTP binding domain containing 1 1.50 
EML5 echinoderm microtubule associated protein like 5 2.02 
ENO2 enolase 2 (gamma, neuronal) 2.76 
ENO3 enolase 3 (beta, muscle) 1.60 
ENOSF1 enolase superfamily member 1 1.63 
EPAS1 endothelial PAS domain protein 1 2.72 
EPHA5 EPH receptor A5 2.72 
EYA4 eyes absent homolog 4 (Drosophila) 3.18 
FAM102A family with sequence similarity 102, member A 1.78 
FAM135A family with sequence similarity 135, member A 1.56 
FAM13C family with sequence similarity 13, member C 1.57 
FAM21A family with sequence similarity 21, member A 1.87 
FAM21B family with sequence similarity 21, member B 2.24 
FAM21C family with sequence similarity 21, member C 2.02 
FAM27A family with sequence similarity 27, member A 1.57 
FAM40B family with sequence similarity 40, member B 2.88 
FAM53B family with sequence similarity 53, member B 1.57 
FAM70A family with sequence similarity 70, member A 1.93 
FAM86B1 family with sequence similarity 86, member B1 1.67 
FBXO25 F-box protein 25 2.32 
FBXO32 F-box protein 32 1.77 
FICD FIC domain containing 2.70 
FLJ10661 family with sequence similarity 86, member A pseudogene 2.02 
FMN1 formin 1 2.21 
FNIP2 folliculin interacting protein 2 2.58 
FYB FYN binding protein 2.48 
GAB2 GRB2-associated binding protein 2 1.85 
GBAP1 glucosidase, beta, acid pseudogene 1 2.32 
GDF15 growth differentiation factor 15 2.81 
GEM GTP binding protein overexpressed in skeletal muscle 2.49 
GK glycerol kinase 1.82 
GNPDA1 glucosamine-6-phosphate deaminase 1 2.18 
GNPTAB N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 1.65 
GOLGA4 golgin A4 1.92 
GPNMB glycoprotein (transmembrane) nmb 3.93 
GPR56 G protein-coupled receptor 56 1.73 
GREB1 growth regulation by estrogen in breast cancer 1 1.77 
GYPC glycophorin C (Gerbich blood group) 2.11 
HCG4 HLA complex group 4 3.20 
HEATR7A HEAT repeat containing 7A 1.79 
HEXA hexosaminidase A (alpha polypeptide) 1.81 
HEY1 hairy/enhancer-of-split related with YRPW motif 1 2.44 
HEY2 hairy/enhancer-of-split related with YRPW motif 2 1.98 
HIST2H2BF histone cluster 2, H2bf 1.73 
HK2 hexokinase 2 1.96 
HLA-DOB major histocompatibility complex, class II, DO beta 1.63 
HLCS holocarboxylase synthetase 1.68 
HMGCL 3-hydroxymethyl-3-methylglutaryl-CoA lyase 1.60 
HOXB9 homeobox B9 1.74 
HSPB8 heat shock 22kDa protein 8 1.73 
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HSPBAP1 HSPB (heat shock 27kDa) associated protein 1 2.31 
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 1.63 
IFI30 interferon, gamma-inducible protein 30 1.71 
IL6R interleukin 6 receptor 1.77 
ILVBL ilvB (bacterial acetolactate synthase)-like 1.54 
INPP4B inositol polyphosphate-4-phosphatase, type II, 105kDa 1.57 
INSIG1 insulin induced gene 1 1.74 
IVNS1ABP influenza virus NS1A binding protein 1.60 
KANK1 KN motif and ankyrin repeat domains 1 1.87 
KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 1.57 
KCNH1 potassium voltage-gated channel, subfamily H (eag-related), member 1 1.97 
KCTD21 potassium channel tetramerisation domain containing 21 1.94 
KCTD7 potassium channel tetramerisation domain containing 7 2.31 
KIAA0415 KIAA0415 1.90 
KIAA1009 KIAA1009 1.67 
KIAA1632 KIAA1632 1.69 
KIAA1671 KIAA1671 1.52 
KIAA1737 KIAA1737 1.82 
KIAA1919 KIAA1919 1.85 
KIF3C kinesin family member 3C 1.90 
KLF15 Kruppel-like factor 15 2.67 
KLF3 Kruppel-like factor 3 (basic) 1.53 
KLHDC1 kelch domain containing 1 1.51 
KLHL24 kelch-like 24 (Drosophila) 1.79 
KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 1.54 
KRTAP4-7 keratin associated protein 4-7 5.40 
KU-MEL-3 KU-MEL-3 2.40 
LACTB2 lactamase, beta 2 1.75 
LAT linker for activation of T cells 1.63 
LCORL ligand dependent nuclear receptor corepressor-like 1.77 
LGALS3 lectin, galactoside-binding, soluble, 3 1.74 
LNX2 ligand of numb-protein X 2 1.69 
LOC25845 hypothetical LOC25845 1.60 
LOC285033 hypothetical protein LOC285033 1.59 
LOC402778 CD225 family protein FLJ76511 1.63 
LOC440957 similar to CG32736-PA 2.07 
LOC654433 hypothetical LOC654433 1.86 
LONRF3 LON peptidase N-terminal domain and ring finger 3 2.65 
LRCH2 leucine-rich repeats and calponin homology (CH) domain containing 2 1.93 
LRRC37B leucine rich repeat containing 37B 1.53 
LRRC48 leucine rich repeat containing 48 1.54 
LY96 lymphocyte antigen 96 3.29 
LYPLAL1 lysophospholipase-like 1 2.03 
LYST lysosomal trafficking regulator 1.77 
MAGI2 membrane associated guanylate kinase, WW and PDZ domain containing 2 3.05 
MARK1 MAP/microtubule affinity-regulating kinase 1 1.76 
MBP myelin basic protein 1.72 
MCOLN1 mucolipin 1 1.56 
MCOLN3 mucolipin 3 2.29 
MCTP1 multiple C2 domains, transmembrane 1 1.78 
MFSD1 major facilitator superfamily domain containing 1 1.63 
MITD1 MIT, microtubule interacting and transport, domain containing 1 1.59 
MLPH melanophilin 1.84 
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MOSPD1 motile sperm domain containing 1 1.91 
MRAS muscle RAS oncogene homolog 2.35 
MREG melanoregulin 2.13 
MRGPRX4 MAS-related GPR, member X4 3.18 
MTHFR methylenetetrahydrofolate reductase (NAD(P)H) 1.89 
MXI1 MAX interactor 1 1.51 
NAV2 neuron navigator 2 2.25 
NCRNA00169 non-protein coding RNA 169 1.83 
NEURL2 neuralized homolog 2 (Drosophila) 1.59 
NEURL3 neuralized homolog 3 (Drosophila) pseudogene 2.01 
NOTCH2NL Notch homolog 2 (Drosophila) N-terminal like 1.51 
NOV nephroblastoma overexpressed gene 5.75 
NPC1 Niemann-Pick disease, type C1 2.19 
NRIP3 nuclear receptor interacting protein 3 1.55 
NT5DC3 5'-nucleotidase domain containing 3 1.53 
NUPR1 nuclear protein, transcriptional regulator, 1 2.18 
OSBPL1A oxysterol binding protein-like 1A 2.62 
OXCT1 3-oxoacid CoA transferase 1 1.56 
P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 2.13 
P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7 2.77 
PBLD phenazine biosynthesis-like protein domain containing 1.50 
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) 1.78 
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 2.36 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 3.64 
PIK3C2B phosphoinositide-3-kinase, class 2, beta polypeptide 1.52 
PLA2G16 phospholipase A2, group XVI 1.69 
PLA2G4C phospholipase A2, group IVC (cytosolic, calcium-independent) 2.56 
PLA2G6 phospholipase A2, group VI (cytosolic, calcium-independent) 1.61 
PLEKHF1 pleckstrin homology domain containing, family F (with FYVE domain) 1 2.21 
PLEKHF2 pleckstrin homology domain containing, family F (with FYVE domain) 2 1.57 
PLEKHM1 pleckstrin homology domain containing, family M (with RUN domain) 1 2.42 
PLEKHM1P pleckstrin homology domain containing, family M (with RUN domain) 1 PsG 1.50 
PLK3 polo-like kinase 3 (Drosophila) 2.46 
PLLP plasma membrane proteolipid (plasmolipin) 1.89 
PLSCR1 phospholipid scramblase 1 1.58 
PNLIPRP3 pancreatic lipase-related protein 3 11.79 
PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 9.04 
PPFIBP2 PTPRF interacting protein, binding protein 2 (liprin beta 2) 2.26 
PPP1R3B protein phosphatase 1, regulatory (inhibitor) subunit 3B 1.58 
PPP1R3C protein phosphatase 1, regulatory (inhibitor) subunit 3C 1.71 
PQLC2 PQ loop repeat containing 2 1.68 
PRDM4 PR domain containing 4 1.90 
PRICKLE2 prickle homolog 2 (Drosophila) 1.52 
PSEN2 presenilin 2 (Alzheimer disease 4) 1.80 
PSG4 pregnancy specific beta-1-glycoprotein 4 2.97 
PTGES prostaglandin E synthase 2.11 
QDPR quinoid dihydropteridine reductase 1.70 
RAB3A RAB3A, member RAS oncogene family 1.72 
RAB9A RAB9A, member RAS oncogene family 1.53 
RAD51L1 RAD51-like 1 (S. cerevisiae) 1.51 
RAD9A RAD9 homolog A (S. pombe) 1.85 
RANBP10 RAN binding protein 10 2.07 
RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 2.93 
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RASSF3 Ras association (RalGDS/AF-6) domain family member 3 1.50 
RCBTB1 RCC1 and BTB (POZ) domain containing protein 1 1.64 
RCL1 RNA terminal phosphate cyclase-like 1 1.71 
RENBP renin binding protein 2.19 
RGPD5 RANBP2-like and GRIP domain containing 5 1.79 
RIMKLB ribosomal modification protein rimK-like family member B 1.62 
RNF144A ring finger protein 144A 1.61 
RPS6KA5 ribosomal protein S6 kinase, 90kDa, polypeptide 5 1.98 
RRAGD Ras-related GTP binding D 4.39 
RTN4RL2 reticulon 4 receptor-like 2 2.21 
RUFY3 RUN and FYVE domain containing 3 2.09 
RUNDC2C RUN domain containing 2C 1.99 
SCD stearoyl-CoA desaturase (delta-9-desaturase) 1.66 
SDSL serine dehydratase-like 1.56 
SEMA6A semaphorin 6A 1.85 
SEPHS2 selenophosphate synthetase 2 1.64 
SEPT3 septin 3 1.55 
SERINC5 serine incorporator 5 2.53 
SETD4 SET domain containing 4 1.76 
SETDB2 SET domain, bifurcated 2 6.95 
SGSH N-sulfoglucosamine sulfohydrolase 1.57 
SH3BP5 SH3-domain binding protein 5 (BTK-associated) 1.64 
SIK1 salt-inducible kinase 1 1.54 
SIRPA signal-regulatory protein alpha 2.22 
SLAMF7 SLAM family member 7 5.82 
SLC16A6 solute carrier family 16, member 6 (monocarboxylic acid transporter 7) 4.10 
SLC19A2 solute carrier family 19 (thiamine transporter), member 2 2.54 
SLC25A25 solute carrier family 25 (mitochondrial carrier; phosphate carrier), 25 2.26 
SLC25A26 solute carrier family 25, member 26 1.68 
SLC26A11 solute carrier family 26, member 11 1.51 
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 1.50 
SLC36A1 solute carrier family 36 (proton/amino acid symporter), member 1 1.84 
SLC38A6 solute carrier family 38, member 6 1.94 
SLC38A7 solute carrier family 38, member 7 2.01 
SLC43A1 solute carrier family 43, member 1 1.67 
SLC9A9 solute carrier family 9 (sodium/hydrogen exchanger), member 9 2.20 
SLCO4A1 solute carrier organic anion transporter family, member 4A1 2.38 
SLFN5 schlafen family member 5 1.79 
SNX10 sorting nexin 10 1.51 
SNX25 sorting nexin 25 1.61 
SNX8 sorting nexin 8 1.81 
SOAT1 sterol O-acyltransferase 1 1.74 
SORD sorbitol dehydrogenase 1.57 
SPHK1 sphingosine kinase 1 2.21 
SPINK1 serine peptidase inhibitor, Kazal type 1 3.20 
SPIRE1 spire homolog 1 (Drosophila) 1.76 
SPSB1 splA/ryanodine receptor domain and SOCS box containing 1 2.49 
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 2.08 
STAG3L4 stromal antigen 3-like 4 1.55 
STARD10 StAR-related lipid transfer (START) domain containing 10 1.59 
STK16 serine/threonine kinase 16 1.52 
STK17B serine/threonine kinase 17b 1.80 
STX7 syntaxin 7 2.30 
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SULT1C2 sulfotransferase family, cytosolic, 1C, member 2 2.20 
SYNC syncoilin, intermediate filament protein 1.98 
SYT14 synaptotagmin XIV 1.80 
TAF4B TAF4b RNA polymerase II, TBP-associated factor, 105kDa 2.26 
TAP2 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 1.72 
TBC1D14 TBC1 domain family, member 14 2.34 
TBC1D16 TBC1 domain family, member 16 1.61 
TBC1D7 TBC1 domain family, member 7 5.48 
TM4SF19 transmembrane 4 L six family member 19 9.91 
TMEM117 transmembrane protein 117 2.58 
TMEM144 transmembrane protein 144 1.59 
TMEM150A transmembrane protein 150A 1.63 
TMEM229B transmembrane protein 229B 1.54 
TMEM232 transmembrane protein 232 2.40 
TMEM38B transmembrane protein 38B 2.71 
TMEM55A transmembrane protein 55A 1.53 
TMEM86A transmembrane protein 86A 1.67 
TNFRSF14 tumor necrosis factor receptor superfamily, member 14 4.79 
TOM1 target of myb1 (chicken) 1.62 
TOP3B topoisomerase (DNA) III beta 1.91 
TP53INP1 tumor protein p53 inducible nuclear protein 1 1.76 
TPCN1 two pore segment channel 1 2.23 
TPI1P2 triosephosphate isomerase 1 pseudogene 2 1.68 
TPP1 tripeptidyl peptidase I 1.66 
TPRA1 transmembrane protein, adipocyte asscociated 1 1.76 
TRAF5 TNF receptor-associated factor 5 2.39 
TRAK1 trafficking protein, kinesin binding 1 1.62 
TRAK2 trafficking protein, kinesin binding 2 1.69 
TRAPPC2L trafficking protein particle complex 2-like 2.07 
TRIB3 tribbles homolog 3 (Drosophila) 1.96 
TRIM63 tripartite motif-containing 63 1.72 
TSPAN10 tetraspanin 10 1.76 
TTYH2 tweety homolog 2 (Drosophila) 1.63 
UAP1L1 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 2.48 
UCK1 uridine-cytidine kinase 1 1.56 
UCN2 urocortin 2 5.25 
UPP1 uridine phosphorylase 1 2.32 
USP2 ubiquitin specific peptidase 2 1.65 
VAC14 Vac14 homolog (S. cerevisiae) 1.85 
VAT1 vesicle amine transport protein 1 homolog (T. californica) 1.66 
VGF VGF nerve growth factor inducible 2.68 
VPS11 vacuolar protein sorting 11 homolog (S. cerevisiae) 1.61 
VPS18 vacuolar protein sorting 18 homolog (S. cerevisiae) 1.93 
WDFY1 WD repeat and FYVE domain containing 1 1.55 
WDR81 WD repeat domain 81 2.51 
WDSUB1 WD repeat, sterile alpha motif and U-box domain containing 1 1.91 
WIPI1 WD repeat domain, phosphoinositide interacting 1 2.07 
XYLB xylulokinase homolog (H. influenzae) 1.57 
YOD1 YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) 1.50 
ZBTB1 zinc finger and BTB domain containing 1 1.55 
ZBTB25 zinc finger and BTB domain containing 25 1.90 
ZC3H6 zinc finger CCCH-type containing 6 1.66 
ZCCHC14 zinc finger, CCHC domain containing 14 2.42 
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ZFYVE16 zinc finger, FYVE domain containing 16 2.54 
ZFYVE26 zinc finger, FYVE domain containing 26 1.53 
ZNF330 zinc finger protein 330 1.90 
ZNF438 zinc finger protein 438 1.70 
ZNF57 zinc finger protein 57 1.90 
ZNF610 zinc finger protein 610 1.91 
ZNF616 zinc finger protein 616 1.93 
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Down-regulated genes (p-value < 0.01; Fold Change < -1.5) 
Gene Name Gene Description Fold Change 
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 -1.53 
ACPL2 acid phosphatase-like 2 -1.57 
ADAMTS15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 -1.54 
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 -1.79 
AMIGO2 adhesion molecule with Ig-like domain 2 -1.80 
AMOTL2 angiomotin like 2 -1.52 
ARSJ arylsulfatase family, member J -1.85 
ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) -1.65 
B3GALT2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 -1.56 
BIRC3 baculoviral IAP repeat-containing 3 -1.82 
BMP2 bone morphogenetic protein 2 -1.90 
C10orf10 chromosome 10 open reading frame 10 -1.63 
C10orf81 chromosome 10 open reading frame 81 -2.15 
C1QTNF1 C1q and tumor necrosis factor related protein 1 -1.69 
C1S complement component 1, s subcomponent -1.82 
C21orf70 chromosome 21 open reading frame 70 -1.98 
C3 complement component 3 -3.26 
C5orf13 chromosome 5 open reading frame 13 -1.70 
C6orf138 chromosome 6 open reading frame 138 -1.88 
CCL5 chemokine (C-C motif) ligand 5 -1.76 
CCNE2 cyclin E2 -1.65 
CD96 CD96 molecule -1.58 
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) -2.22 
CDK1 cyclin-dependent kinase 1 -1.57 
COL11A1 collagen, type XI, alpha 1 -1.56 
COL11A2 collagen, type XI, alpha 2 -1.53 
COL12A1 collagen, type XII, alpha 1 -1.58 
CPA4 carboxypeptidase A4 -2.11 
CTGF connective tissue growth factor -2.33 
CXCL1 chemokine (C-X-C motif) lig 1 (melanoma growth stimulating activity, α) -1.73 
CYR61 cysteine-rich, angiogenic inducer, 61 -2.33 
DEPDC7 DEP domain containing 7 -1.57 
DGCR14 DiGeorge syndrome critical region gene 14 -1.51 
DKK1 dickkopf homolog 1 (Xenopus laevis) -1.86 
DOCK4 dedicator of cytokinesis 4 -1.54 
DSEL dermatan sulfate epimerase-like -1.90 
EDIL3 EGF-like repeats and discoidin I-like domains 3 -1.59 
EGR2 early growth response 2 -1.88 
EHF ets homologous factor -1.67 
ENC1 ectodermal-neural cortex 1 (with BTB-like domain) -1.62 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) -1.67 
FAM111B family with sequence similarity 111, member B -1.63 
FBN1 fibrillin 1 -1.68 
FHDC1 FH2 domain containing 1 -1.74 
FLT1 fms-related tyrosine kinase 1 -1.51 
FREM2 FRAS1 related extracellular matrix protein 2 -1.56 
FST follistatin -1.52 
GBP1 guanylate binding protein 1, interferon-inducible, 67kDa -1.87 
GCM1 glial cells missing homolog 1 (Drosophila) -1.61 
GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 -1.60 
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GFPT2 glutamine-fructose-6-phosphate transaminase 2 -1.91 
GJA5 gap junction protein, alpha 5, 40kDa -1.77 
GOLGA8E golgin A8 family, member E -1.53 
GPR84 G protein-coupled receptor 84 -1.91 
HAS2 hyaluronan synthase 2 -1.62 
HOXA2 homeobox A2 -2.93 
HSPG2 heparan sulfate proteoglycan 2 -1.68 
ICAM4 intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) -3.15 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 -1.57 
IGFBP5 insulin-like growth factor binding protein 5 -1.94 
IL1A interleukin 1, alpha -2.46 
IL1B interleukin 1, beta -3.99 
IL32 interleukin 32 -1.57 
IL6 interleukin 6 (interferon, beta 2) -1.92 
IL7R interleukin 7 receptor -2.90 
IL8 interleukin 8 -1.91 
IRAK2 interleukin-1 receptor-associated kinase 2 -1.52 
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) -1.53 
KCNN3 potassium intermediate/small conductance calcium-activated channel, N3 -1.82 
KCNS3 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 -1.52 
KLF4 Kruppel-like factor 4 (gut) -1.58 
KYNU kynureninase (L-kynurenine hydrolase) -1.63 
LOC100289612 arsenic transactivated protein 1 -1.64 
MAMLD1 mastermind-like domain containing 1 -1.53 
MAP3K5 mitogen-activated protein kinase kinase kinase 5 -1.51 
MIR21 microRNA 21 -1.82 
MIRLET7A2 microRNA let-7a-2 -1.80 
MIRLET7I microRNA let-7i -1.61 
MYADM myeloid-associated differentiation marker -1.56 
NAV3 neuron navigator 3 -1.95 
NEDD9 neural precursor cell expressed, developmentally down-regulated 9 -1.54 
NIPAL1 NIPA-like domain containing 1 -1.50 
NR2F1 nuclear receptor subfamily 2, group F, member 1 -1.52 
NR4A1 nuclear receptor subfamily 4, group A, member 1 -1.66 
NR4A2 nuclear receptor subfamily 4, group A, member 2 -1.56 
NRG1 neuregulin 1 -1.53 
NRXN3 neurexin 3 -1.80 
NUAK2 NUAK family, SNF1-like kinase, 2 -2.49 
OASL 2'-5'-oligoadenylate synthetase-like -1.52 
PAPPA pregnancy-associated plasma protein A, pappalysin 1 -2.30 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 -1.67 
PCDH18 protocadherin 18 -1.84 
PCDHB13 protocadherin beta 13 -1.67 
PCDHB14 protocadherin beta 14 -1.75 
PCDHB16 protocadherin beta 16 -1.64 
PCDHB2 protocadherin beta 2 -1.56 
PCDHB3 protocadherin beta 3 -1.51 
PCDHB5 protocadherin beta 5 -1.59 
PCDHB8 protocadherin beta 8 -1.67 
PDE10A phosphodiesterase 10A -1.53 
PDE1C phosphodiesterase 1C, calmodulin-dependent 70kDa -1.52 
PDXDC2 pyridoxal-dependent decarboxylase domain containing 2 -1.75 
PHLDB2 pleckstrin homology-like domain, family B, member 2 -1.56 
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PI15 peptidase inhibitor 15 -1.53 
PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) -1.54 
PMEPA1 prostate transmembrane protein, androgen induced 1 -1.60 
PRDM1 PR domain containing 1, with ZNF domain -1.90 
PTPN22 protein tyrosine phosphatase, non-receptor type 22 (lymphoid) -1.75 
PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 -1.71 
PTX3 pentraxin 3, long -2.47 
PXDN peroxidasin homolog (Drosophila) -1.67 
RALGPS2 Ral GEF with PH domain and SH3 binding motif 2 -1.65 
RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 -1.61 
RCVRN recoverin -3.34 
RNF144B ring finger protein 144B -1.53 
RNU11 RNA, U11 small nuclear -1.52 
RNU1-1 RNA, U1 small nuclear 1 -1.70 
RNU5D RNA, U5D small nuclear -2.11 
S100A7 S100 calcium binding protein A7 -1.55 
SAMD9 sterile alpha motif domain containing 9 -1.53 
SDK1 sidekick homolog 1, cell adhesion molecule (chicken) -1.71 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 -1.51 
SH3PXD2A SH3 and PX domains 2A -1.70 
SHC4 SHC (Src homology 2 domain containing) family, member 4 -1.52 
SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group) -1.53 
SLC5A3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 -1.76 
SLFN11 schlafen family member 11 -1.58 
SLIT2 slit homolog 2 (Drosophila) -1.96 
SLITRK6 SLIT and NTRK-like family, member 6 -2.11 
SNORA68 small nucleolar RNA, H/ACA box 68 -1.70 
SNORD12C small nucleolar RNA, C/D box 12C -1.83 
SNORD14E small nucleolar RNA, C/D box 14E -1.52 
SNORD15B small nucleolar RNA, C/D box 15B -1.59 
SNORD22 small nucleolar RNA, C/D box 22 -1.56 
SNORD26 small nucleolar RNA, C/D box 26 -1.62 
SNORD28 small nucleolar RNA, C/D box 28 -1.53 
SNORD36B small nucleolar RNA, C/D box 36B -1.77 
SNORD36C small nucleolar RNA, C/D box 36C -1.71 
SNORD3A small nucleolar RNA, C/D box 3A -1.52 
SNORD5 small nucleolar RNA, C/D box 5 -1.56 
SNORD76 small nucleolar RNA, C/D box 76 -1.50 
SNORD78 small nucleolar RNA, C/D box 78 -1.52 
SOCS3 suppressor of cytokine signaling 3 -1.58 
SOX2 SRY (sex determining region Y)-box 2 -1.54 
SPATA5L1 spermatogenesis associated 5-like 1 -1.52 
ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -1.55 
ST8SIA5 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 -1.54 
STARD13 StAR-related lipid transfer (START) domain containing 13 -1.75 
TFPI2 tissue factor pathway inhibitor 2 -1.51 
TGFA transforming growth factor, alpha -1.59 
TLR4 toll-like receptor 4 -1.57 
TMEM171 transmembrane protein 171 -1.63 
TMEM2 transmembrane protein 2 -1.60 
TMOD1 tropomodulin 1 -1.52 
TNF tumor necrosis factor -2.20 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 -2.21 
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TNFAIP6 tumor necrosis factor, alpha-induced protein 6 -3.80 
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 -1.71 
TNIK TRAF2 and NCK interacting kinase -1.57 
TRIB1 tribbles homolog 1 (Drosophila) -1.55 
TUBB2B tubulin, beta 2B -1.52 
UBE2C ubiquitin-conjugating enzyme E2C -1.59 
UNC5C unc-5 homolog C (C. elegans) -1.74 
VEGFC vascular endothelial growth factor C -1.79 
WEE1 WEE1 homolog (S. pombe) -1.72 
WNT5A wingless-type MMTV integration site family, member 5A -2.03 
ZFP36 zinc finger protein 36, C3H type, homolog (mouse) -1.58 
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Appendix C – General bacterial expression and purification protocols by PSF 
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Appendix D – General limited proteolysis protocol by PAF 
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